

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

# Universal healthcare coverage, cancer screening and potential barriers to accessing cancer care in Sub-Saharan Africa: The results and implications of a Cross-sectional Community Study in Rural South-West Nigeria

Journal:	BMJ Open
Journal.	
Manuscript ID	bmjopen-2020-040352
Article Type:	Original research
Date Submitted by the Author:	12-May-2020
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

# SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

Universal healthcare coverage, cancer screening and potential barriers to accessing cancer care in Sub-Saharan Africa: The results and implications of a Cross-sectional Community Study in Rural South-West Nigeria

Sharma A. MD<sup>1</sup>, Alatise O. I. MBChB<sup>2</sup>, O'Connell K. MSc<sup>3</sup>, Gbenga O.S. MSc<sup>2</sup>, Aderounmu A.A. MBChB<sup>2</sup>, Samson. M.L. BSc<sup>3</sup>, Wuraola F. MBChB<sup>2</sup>, Olasehinde O. MBChB, Kingham T.P MD<sup>1</sup>, Du M. ScD<sup>3</sup>

<sup>1</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Obafemi Awolowo University, Ile-Ife, Nigeria; <sup>3</sup>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

**Acknowledgments:** The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

**Funding:** This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's Center for Global Health to perform dedicated cancer research in the region. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

# **Correspondence:**

Avinash Sharma

Memorial Sloan Kettering Cancer Center

1275 York Avenue, C-886

New York, NY 10065

avinash.s.sharma@gmail.com

ne to declare Conflicts of Interest: None to declare

#### Author contributions:

#### 1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

## 2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

#### 3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

#### 4. O.S. Gbenga

Author contributions: study organisation, data collection

#### 5. A.A. Aderounmu

Author contributions: study organisation, data collection

#### 6. M.L.Samson

Author contributions: study and questionnaire design

#### 7. F. Wuraola

Author contributions: Manuscript revision

#### 8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

#### 9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

#### 10. **M. Du**

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

# ABSTRACT

**Background/Aims:** Cancer burden is predicted to double by 2030 in sub-Saharan Africa. Accordingly, access to healthcare services for cancer management has been made a priority in the region. In Nigeria, the National Cancer Control Plan aims to ensure greater than 50% cancer screening of eligible populations by 2022 for all Nigerians. This study sought to describe current healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria.

**Methods:** During April 2018, a cross-sectional study of community-based adults (>18 years) was conducted approximately 130 kilometers east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. A validated questionnaire was used to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

**Results:** A total of 346 individuals were enrolled; the median age was 52 years, and 75% of participants were female. Of the entire cohort, only 4% had medical insurance,. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent, with 1.5% of participants reporting having cervical cancer screening and 3.3% of participants >40 years having a mammogram. Colonoscopy screening in those >50 years was 5%. Cancer screening assessment was less frequent in those with less income and lower levels of education. Despite this, we observed that most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exist.

 **Conclusions:** Despite expected increases in cancer cases, our data highlight a deficiency in cancer screening and lack of universal healthcare coverage within a community-based adult Nigerian population. Increasing financial risk protection, awareness, and targeted resource allocation may help expand access.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

# Strengths and Limitations of the study:

- The study provided a contemporary perspective potential barriers to accessing medical and cancer care in rural South-West Nigeria. Recruitment and data collection performed by interviewers fluent in the local dialect who underwent a systematic and rigorous two-day training program.
- Questionnaire tailored to the local population and developed in collaboration with local clinicians, epidemiologists, and nutritionists. Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
- 5) Survey conducted at a single time (mid-week, during the day), which may have affected sample composition (e.g., more females than males).

# INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.<sup>1-3</sup> According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.<sup>4 5</sup> In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.<sup>6-8</sup> Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.<sup>9</sup>

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.<sup>7 10</sup> In the region, out-of-pocket health expenditures are a major contributor to poverty <sup>11-</sup><sup>13</sup>, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.<sup>14</sup> However, uptake has been limited and restricted,<sup>15</sup> and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.<sup>15 16</sup>

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.<sup>17</sup> The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.<sup>17-19</sup> Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

#### **BMJ** Open

> Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."<sup>20</sup> Despite this, the current state of cancer screening and barriers to care in this region (esp. rural areas) are not well-defined. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. In addition, with 50 percent of Nigeria's population living in rural areas<sup>21</sup> we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

> This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria<sup>22</sup> investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.<sup>6 19 20 23</sup> Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

# METHODS

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns Ijebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the

**BMJ** Open

main tertiary referral center in the region. The study was approved by the Obafemi Awolowo University institutional ethics review committee.

## Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Based on the resource capacity of each town hall and the size of each community, enrolment was to be capped at a maximum of 300 participants at ljebu-Jesa and 100 at Ere-Jesa. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained research assistant. All research assistants underwent a two-day training program that involved education in the research aims, methodology, and ethics as well as interview techniques and the use of electronic tablets for recording data. The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication

#### **BMJ** Open

use, and environmental exposures. Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. The questionnaire, developed in collaboration with local clinicians, epidemiologists, and nutritionists, was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,<sup>24</sup> Nigeria General Household Survey,<sup>25</sup> World Health Organization-endorsed Global Physical Activity Questionnaire,<sup>26</sup> and the Nurses' Health Study questionnaire.<sup>27-30</sup> Demographic and socioeconomic data collected from our study population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator <sup>31 32</sup> to assess external validity.

## Statistical analysis

#### **BMJ** Open

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

# RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed. Enrolment was capped at this number to ensure complete surveys could be conducted for all individuals. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

## Table 1: Demographic characteristics of the study group (n=346)

#### (n=268 ljebu-Jesa, n=68 Ere-Jesa)

Variable	n (%)
Median Age, years (range)	52 (18-100)
Sex	
Male	85 (24.6)
Female	261 (75.4)
Marital Status	
Single	27 (7.8)
Married	213 (61.6)
Other (Divorced/cohabiting)	106 (30.6)
Tribe	
Yoruba	332 (96.0)
lbo	5 (1.4)

2	
3	
2	
4	
2 3 4 5 6 7 8 9 1	
6	
7	
, 0	
ð	
9	
1	0
1	1
	ר
1	2 3
1	3
1	4
1	5
1	6
1	-
I	/
1	8
1	9
2	5 6 7 8 9 0
้า	1
2	1
2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3	2 3
2	3
2	23456780
2	5
2	2
2	6
2	7
2	8
2	9 0
2	^
5	0
3	1
3	2 3
3	3
2	5 6 7 8
2	4
3	5
3	6
3	7
3	Q
3	
	0
4	1
4	2
4	
4	
4	
4	6
4	
4	
4	
5	0
5	
5	
5	3
5	4
5	5
	6
_	_ _
5	7
-	8
5	9
6	
0	5

Other	9 (2.6)
Religion	
Christian	326 (94.2)
Muslim	19 (5.5)
Other	1 (0.3)
Education	
No formal education	88 (25.4)
Primary	92 (26.6)
Secondary	92 (26.6)
Vocational/Technical	45 (13.0)
Higher	29 (8.4)
Occupation	
Unemployed	30 (8.7)
Civil servant	30 (8.7)
Trader	123 (35.5)
Farmer	35 (10.1)
Self-employed	80 (23.1)
Other	48 (13.9)
Number of Live Births (Females, n=242)	
0	6 (2.5)
1	15 (6.2)
2	23 (9.5)
3	28 (11.6)
4	54 (22.3)
5 or more	116 (47.9)

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian Demographic and Health Survey (**Table 2b**).<sup>31</sup> Both groups had similar degrees of

education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,<sup>32</sup> our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

		1
Variable		n (%)
Personal income (per mor	nth, in Naira)	
	<10,000	155 (44.8)
	10,000-49,999	139 (40.2)
	50,000-99,999	26 (7.5)
	100,000-249,999	16 (4.6)
	250,000-499,999	9 (2.6)
	≥500,000	1 (0.3)
Family income (per month	, in Naira)	
	<10,000	117 (33.8)
	10,000-49,999	147 (42.5)
	50,000-99,999	38 (11.0)
	100,000-249,999	28 (8.1)
	250,000-499,999	11 (3.2)
	≥500,000	5 (1.4)
Type of dwelling		
	Own apartment	131 (37.9)
	Rent apartment	146 (42.2)
	Family house	67 (19.4)
	Other	2 (0.6)
Type of toilet		
	Water system	151 (43.6)
	Pit latrine	164 (47.4)
	Bush	23 (6.6)
	Bucket	7 (2.0)
	Other	1 (0.3)
Water source		
	Pipe borne/boreholes	185 (53.5)

# Table 2a: Income and household conditions

	Well	146 (42.2)
	River	15 (4.3)
Appliances		
	Electricity	318 (91.9)
	Television	262 (75.7)
	Radio	251 (72.5)
	Refrigerator	154 (44.5)
	Air conditioner	8 (2.3)
	Generating set	99 (28.6)
	Personal computer	38 (11.0)
	None	18 (5.2)

# Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

	NDHS Urban (%)	NDHS Rural (%)	NDHS Total (%)	Current study (%)
Cooking Fuel				
Electricity	0.7	0.2	0.4	10.7
Liquefied petroleum gas/natural	4.6	0.5	2.3	21.1
Gas/biogas				
Kerosene	47.6	8.7	25.5	31.8
Charcoal	5.3	1.6	3.2	2.3
Wood	37.9	83.3	63.7	34.1
Electricity				
Yes	83.6	34.4	55.6	91.9
No	16.3	65.4	44.2	8.1
Missing	0.1	0.2	0.2	0
Household Appliances				
Radio	77.7	61.3	68.3	72.5
Television	73.2	28.2	47.6	75.7
Refrigerator	32.5	7.5	18.3	44.5
Means of Transportation				
Bicycle	12.7	18.3	18.3	0.9
Motorcycle/scooter	27.0	31.2	31.2	15.0
Car/truck	14.4	8.7	8.7	12.1
Education				
	NDHS	NDHS	Current	Current study
	Female	Male	study	Male
	(%)	(%)	Female	(%)
			(%)	
No formal education	37.8	21.2	28.7	15.3
Primary	17.3	16.7	26.8	25.9
Secondary	35.8	47.7 14.3	28.0	22.4
Secondary			16.5	36.5

(4/267) of female participants had a previous cervical smear/assessment, and 3%

#### **BMJ** Open

(6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was also infrequent.

visit
(if female > 21, n = 261) Previous mammogram (if female >40, n = 183) Previous colonoscopy (if >50 years, n = 190) Last primary health care physician visit4 (1.5) 6 (3.3)Last primary health care physician visit9 (4.5) $<1$ year ago $1-4$ years ago $5-10$ years ago >10 years ago180 (52.0) $32 (9.2)$ $41 (11.8)$ Last time seen traditional healer $<2$ years ago $\geq 2$ years ago254 (73.4) $26 (7.5)$
Previous mammogram (if female >40, n = 183) Previous colonoscopy (if >50 years, n = 190)6 (3.3)Last primary health care physician visit9 (4.5) $<1$ year ago $1-4$ years ago $5-10$ years ago >10 years ago180 (52.0) $<2$ years ago $<254 (73.4)$ $<2$ years ago $<22$ years ago26 (7.5)
female >40, $n = 183$ ) Previous colonoscopy (if >50 years, $n = 190$ )6 (3.3)Last primary health care physician visit9 (4.5) $<1$ year ago $1-4$ years ago $5-10$ years ago >10 years ago180 (52.0) $<200$ $2-10$ years ago $2-10$ years ago <br< td=""></br<>
Previous colonoscopy (if >50 years, n = 190)9 (4.5)Last primary health care physician visit9 (4.5) $<1$ year ago $1-4$ years ago $5-10$ years ago >10 years ago93 (26.9) $32 (9.2)$ $41 (11.8)$ Last time seen traditional healer Never254 (73.4) $66 (19.1)$ $22$ years ago $<2$ years ago26 (7.5)
years, n = 190)9 (4.5)Last primary health care physician visit9 (4.5)<1 year ago 1-4 years ago 5-10 years ago >10 years ago180 (52.0) 93 (26.9) 32 (9.2) 41 (11.8)Last time seen traditional healer Never94.5)Never $\leq 2$ years ago254 (73.4) 66 (19.1) 26 (7.5)
visit <1 year ago 1-4 years ago 5-10 years ago >10 years ago 254 (73.4) <2 years ago 26 (7.5)
<1 year ago180 (52.0)1-4 years ago93 (26.9)5-10 years ago32 (9.2)>10 years ago41 (11.8)Never254 (73.4)<2 years ago
$1-4$ years ago $93 (26.9)$ $5-10$ years ago $32 (9.2)$ >10 years ago $41 (11.8)$ Last time seen traditional healerNever $254 (73.4)$ $254 (73.4)$ $<2$ years ago $66 (19.1)$ $\geq 2$ years ago $26 (7.5)$
5-10 years ago       32 (9.2)         >10 years ago       41 (11.8)         Last time seen traditional healer       254 (73.4)         <2 years ago
>10 years ago41 (11.8)Last time seen traditional healerNever $254 (73.4)$ <2 years ago
Last time seen traditional healer Never 254 (73.4) <2 years ago 66 (19.1) ≥2 years ago 26 (7.5)
Never254 (73.4)<2 years ago
<2 years ago 66 (19.1) ≥2 years ago 26 (7.5)
≥2 years ago 26 (7.5)
<b>Hypertension</b> 110 (31.8)
<b>Diabetes</b> 16 (4.6)
High cholesterol 24 (6.9)
Stroke 18 (5.2)
Alcohol use*
No 227 (65.6)
Yes, drank in past, but quit 65 (18.8)
Yes, currently drink alcohol 54 (15.6)
Smoking status*
Never 303 (87.6)
Ever 43 (12.4)
Medication use

# Table 3: Screening activities, access to medical services, and health conditions

Reported anti-hypertensive use	78 (22.5)
Reported aspirin use	89 (25.7)
Reported anti-cholesterol use	7 (2.0)
Reported herbal supplement use	233 (67.3)
Oral contraceptive use	
Never	175 (67.0)
Past use	64 (24.5)
Current use	22 (8.4)

Participants were asked "Have you had 10 or more drinks of alcohol in your life?"
 Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Т

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals, with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

#### Table 4: Insurance coverage and medical costs

Variable		n (%)
Insurance		
	No	331 (95.7)
	Yes	15 (4.3)
Last time used insurance		

In the last 2 years	6 (40.0)
>2 years ago	9 (60.0)
How many family members covered by insurance	
None	331 (95.7)
1-2	8 (2.3)
3-4	3 (0.9)
5 or more	4 (1.2)
Reasons for not having insurance (n=331)	
Expense	32 (9.7)
Lack of coverage	13 (3.9)
Too difficult to access	73 (22.1)
Other	217 (65.6)
Major medical costs in the last 2 years	
No	186 (53.8)
Yes	160 (46.2)
Estimated amount	
<10,000 Naira	73 (45.6)
10,000-49,000 Naira	38 (23.8)
50,000-99,999 Naira	16 (10.0)
>100,000 Naira	22 (13.8)
Unknown	11 (6.9)
Reasons for major medical costs (n=158)	
Surgery	17 (10.8)
Chronic conditions	52 (32.9)
Acute illness/trauma	74 (46.8)
Other/multiple reasons	15 (9.5)
Amount spent (continuous)	10,000 (50-
Overall median (range)	1,500,000)
Median amount spent by reason (range)	
Surgery	60,000 (7,000- 150,000)
Chronic conditions	18,000 (500- 150,000)
Acute illness/trauma	5,000 (50-400,000) 70,000 (800-
Other/multiple reasons	500,000)

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education **Table 5**. Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels

**BMJ** Open

of education. No significant relationship was observed by insurance status or other factors that were assessed. In a multivariate logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

# Table 5: Association between Cancer Screening Activity and Income, Insurance and Education N =310<sup>+</sup>

Variable	Cancer Screening (N=17)	No Cancer Screening (N=293)	P value*	
Personal income (per month, in				
Naira)				
<10,000	2/138 (1.5)	140/138 (98.5)		
10,000-49,999	9/122 (7.4)	115/122 (92.6)	<0.01	
>50,000	6/43 (14.0)	38/43 (86.0)		
Family income (per month, in				
Naira)				
<10,000	1/108 (0.9)	107/108 (99.1)		
10,000-49,999	8/129(6.2)	121/129(93.8)	<0.01	
>50,000	8/66 (12.1)	58/66 (87.9)		
Insurance Status				
No	15/290 (5.2)	275/290 (94.8)	0.10	
Yes	2/13 (15.4)	11/13 (84.6)	0.12	
Education				
No formal education	1/86 (1.2)	85/86 (98.8)		
Primary	3/83 (3.6)	80/83 (96.4)		
Secondary	8/78 (10.3)	70/78 (89.7)	0.04	
Higher	5/56 (8.9)	51/56 (91.1)		

No association by Gender, Marital Status, Religion

\* Adjusted for eligible population, whereby cancer screening activities defined as history of cervical assessment in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years

\* Fisher's exact test for association

# DISCUSSION

We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), <sup>6 19 33</sup> were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)<sup>31</sup> and likely represent broad health and development deficiencies present in the community.

Previous studies conducted in the region <sup>34-42</sup> have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.<sup>5</sup> <sup>43</sup> This highlights a need to develop sound health infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking and that the potential cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.<sup>35</sup> <sup>36</sup> <sup>44-47</sup> The Nigerian "National Cancer Control Plan 2018-2022," specifically details goals to make screening services

#### **BMJ** Open

and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.<sup>20</sup>. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022.<sup>20</sup> We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Our analysis provides some idea of how individuals have navigated health system and their degree of engagement different levels.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary alternative for early detection in low-resource settings.<sup>19</sup> <sup>45</sup> <sup>48</sup> This has been recommended in local policy and was not assessed in the current study.<sup>20</sup> Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty

#### **BMJ** Open

as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.<sup>49</sup> Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.<sup>50 51</sup> Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.<sup>14 15</sup> Recent reports confirm that this expansion has been limited in Nigeria. In line with previous studies, our data indicate that the NHIS is severely underutilized in the community population.<sup>15 16</sup> The state health insurance scheme has been instituted in

only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. <sup>15</sup>

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.<sup>16</sup> However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.<sup>52</sup> Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region <sup>53 54</sup>, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.<sup>35 42 44 55</sup> In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.<sup>56</sup> In addition, "demand-side" approaches to resource allocation, such as the stipend we provided for travel in the

#### **BMJ** Open

study or e-vouchers,<sup>57 58</sup> are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated questionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition (e.g., resulted in more females than males). Nevertheless, overall consistency with national demographic indicators (e.g., income, education, and living conditions) indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.<sup>31 32</sup>

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this, including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

$     \begin{array}{r}       1 \\       2 \\       3 \\       4 \\       5 \\       6 \\       7 \\       8 \\       9 \\       10 \\       11 \\       12 \\       13 \\       14 \\       15 \\       16 \\       17 \\       18 \\       19 \\       20 \\       21 \\       22 \\       23 \\       24 \\       25 \\       26 \\       27 \\       28 \\       29 \\       30 \\       31 \\       32 \\       33 \\       34 \\       35 \\       36 \\       37 \\       38 \\       39 \\       40 \\       41 \\       42 \\       43 \\       44 \\       45 \\       46 \\       47 \\       48 \\       49 \\       50 \\      50 \\      50 \\      50 \\      50 \\      50 \\      50 \\   $	
46	
48	
50 51	
52	
53 54	
54	

# REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. BMJ Case Reports 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. *Bull World Health Organ* 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

4

5

6 7

8

9

10

11

12 13

14

15

16

17 18

19

20

21

22

23 24

25

26

27

28 29

30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57

58

- Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- 15. Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. *Int J Health Policy Manag* 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- 22. Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- 25. National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

*journal of public health* 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. REPRODUCIBILITY AND VALIDITY OF A SEMIQUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. *Eur J Cancer Care (Engl)* 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 35. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. *Cancer Causes & Control* 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- 36. Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. Journal of Global Oncology 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 37. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
   [published Online First: 2016/12/30]
- 38. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]
- Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. Asian Pac J Cancer Prev 2010;11(1):137-40. [published Online First: 2010/07/03]
- 40. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 41. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]

- 42. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 43. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- 44. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- 45. Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- 46. Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 47. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- 49. Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 50. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 51. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. World J Surg 2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]
- 52. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 53. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 54. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and

1	
2	
3	
3 4	
5	
6	
7	
8	
9	
10	
11	
11 12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
22	
23	
24	
25	
26	
27	
28	
20 29	
30	
50	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
40 49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: https://doi.org/10.1016/S0140-6736(17)30874-7

- 55. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 56. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. *JMIR Mhealth Uhealth* 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 57. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 2018-000276 58. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

# **BMJ Open**

# Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040352.R1
Article Type:	Original research
Date Submitted by the Author:	02-May-2021
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics
<b>Primary Subject Heading</b> :	Global health
Secondary Subject Heading:	Oncology, Health services research, Public health
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT
	·





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Sharma A. MD<sup>1</sup>, Alatise O. I. MBChB<sup>2</sup>, O'Connell K. MSc<sup>3</sup>, Gbenga O.S. MSc<sup>2</sup>, Aderounmu A.A. MBChB<sup>2</sup>, Samson. M.L. BSc<sup>3</sup>, Wuraola F. MBChB<sup>2</sup>, Olasehinde O. MBChB, Kingham T.P MD<sup>1</sup>, Du M. ScD<sup>3</sup>

<sup>1</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Obafemi Awolowo University, Ile-Ife, Nigeria; <sup>3</sup>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

**Acknowledgments:** The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

**Funding:** This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's Center for Global Health to perform dedicated cancer research in the region. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

#### **Correspondence:**

# Avinash Sharma

1	
2 3 4	Memorial Sloan Kettering Cancer Center
5	1275 York Avenue, C-886
7 8	New York, NY 10065
9 10 11	avinash.s.sharma@gmail.com
12 13 14	
14 15 16	Conflicts of Interest: None to declare
17 18 19	
20 21	
22 23 24	
24 25 26	
27 28 29	
30 31	
32 33 34	
35 36	
37 38 39	
40 41	
42 43 44	
44 45 46	
47 48 49	
50 51	
52 53	
54 55 56	
57 58	
59 60	

#### Author contributions:

### 1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

# 2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

# 3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

### 4. O.S. Gbenga

Author contributions: study organisation, data collection

# 5. A.A. Aderounmu

Author contributions: study organisation, data collection

#### 6. M.L.Samson

Author contributions: study and questionnaire design

# 7. F. Wuraola

Author contributions: Manuscript revision

# 8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

### 9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

#### 10. **M. Du**

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

¢

# ABSTRACT

 **Background/Aims:** Cancer burden is predicted to double by 2030 in sub-Saharan Africa. Accordingly, access to healthcare services for cancer management has been made a priority in the region. In Nigeria, the National Cancer Control Plan aims to ensure greater than 50% cancer screening of eligible populations by 2022 for all Nigerians. This study sought to describe current healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria.

**Methods:** During April 2018, a cross-sectional study of community-based adults (>18 years) was conducted approximately 130 kilometers east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. A questionnaire was used to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

**Results:** A total of 346 individuals were enrolled; the median age was 52 years, and 75% of participants were female. Of the entire cohort, only 4% had medical insurance,. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent, with 1.5% of participants reporting having cervical cancer screening and 3.3% of participants >40 years having a mammogram. Colonoscopy screening in those >50 years was 5%. Cancer screening assessment was less frequent in those with less income and lower levels of education. Despite this, we observed that most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exist.

**Conclusions:** Despite expected increases in cancer cases, our data highlight a deficiency in cancer screening and lack of universal healthcare coverage within a

community-based adult Nigerian population. Increasing financial risk protection, awareness, and targeted resource allocation may help expand access.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

# Strengths and Limitations of the study:

- The study provided a contemporary perspective potential barriers to accessing medical and cancer care in rural South-West Nigeria. Recruitment and data collection performed by interviewers fluent in the local dialect who underwent a systematic and rigorous two-day training program.
- Questionnaire tailored to the local population and developed in collaboration with local clinicians, epidemiologists, and nutritionists. Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
- 5) Survey conducted at a single time (mid-week, during the day) in two geographic locations, which may have affected sample composition (e.g., more females than males).

# INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.<sup>1-3</sup> According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.<sup>4 5</sup> In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.<sup>6-8</sup> Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.<sup>9</sup>

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.<sup>7 10</sup> In the region, out-of-pocket health expenditures are a major contributor to poverty <sup>11-</sup><sup>13</sup>, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.<sup>14</sup> However, uptake has been limited and restricted,<sup>15</sup> and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.<sup>15 16</sup>

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.<sup>17</sup> The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.<sup>17-19</sup> Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

#### **BMJ** Open

> Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."<sup>20</sup> Despite this, the current state of cancer screening activities and barriers to care in this region (esp. rural areas) are not well-defined or documented. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. National programmes for screening breast and cervical cancer are lacking. Typically, screening interactions occur at primary health care facilities or community health clinics – often for women when they are being seen during pregnancy or for other related health issues such as immunisations. Screening services for cervical and breast cancer have been implemented sporadically by both government and non-government organisations but predominantly in urban areas. The overwhelming majority of individuals in the region are symptomatic when they present with disease. With 50 percent of Nigeria's population living in rural areas<sup>21</sup> we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

> This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria<sup>22</sup> investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.<sup>6 19 20 23</sup> Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

# METHODS

# Study Design/Setting

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns ljebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the main tertiary referral center in the region. This study was part of a broader capacity building project in the region to improve cancer care. It was a baseline study to assess access to cancer services but also explore unique risk factors for cancer – such as diet, exercise, microbial and environmental exposures. The study was approved by the Obafemi Awolowo University institutional ethics review committee.

# Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized all potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Participants were notified of the study through discussion at the weekly local community meetings in the month leading up to the study, advertisements on local radio-stations and through community workers visiting regional sites.

# Participants

 Adults >18 years in the two towns were invited to participate. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Based on the resource capacity of each town hall and the size of each community, enrolment was to be capped at a maximum of 300 participants at ljebu-Jesa and 100 at Ere-Jesa. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

# Questionnaire

The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication use, and environmental exposures. The questionnaire used was developed in collaboration with local clinicians, epidemiologists, and nutritionists, and was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,<sup>24</sup> Nigeria General Household Survey,<sup>25</sup> World Health Organization-endorsed Global Physical Activity Questionnaire,<sup>26</sup> and the Nurses' Health Study questionnaire.<sup>27-30</sup>

# Data collection

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained

**BMJ** Open

research assistant. All research assistants underwent a two-day training program that involved education into the research aims, methodology, and ethics as well as interview techniques through role paying exercise, pilot testing of the questionnaire and the use of electronic tablets for recording data.

# Outcome measures

Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. Demographic and socioeconomic data collected from our study population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator <sup>31 32</sup> to assess external validity.

# Statistical analysis

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard

deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. Missing data were not possible for completed questionnaires as only complete responses to questions could be processed in order to advance the survey on the electronic tablets. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

# RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed. Enrolment was capped at this number to ensure complete surveys could be conducted for all individuals. All individuals that were interviewed provided data for analysis. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

Table 1: Demographic characteristics of the study group (n=346)

#### (n=268 ljebu-Jesa, n=68 Ere-Jesa)

Variable	n (%)
Median Age, years (range)	52 (18-100)
Sex	
Male	85 (24.6)
Female	261 (75.4)
Marital Status	
Single	27 (7.8)
Married	213 (61.6)
Other (Divorced/cohabiting)	106 (30.6)
Tribe	

Yoruba	332 (96.0)
Ibo	5 (1.4)
Other	. ,
Religion	9 (2.6)
Christian	326 (94.2)
Muslim	19 (5.5)
Other	1 (0.3)
Education	1 (0.3)
No formal education	88 (25.4)
Primary	92 (26.6)
Secondary	92 (20.0) 92 (26.6)
Vocational/Technical	45 (13.0)
Higher	43 (13.0) 29 (8.4)
Occupation	29 (0.4)
Unemployed	30 (8.7)
Civil servant	30 (8.7)
Trader	123 (35.5)
Farmer	35 (10.1)
Self-employed	80 (23.1)
Other	48 (13.9)
Number of Live Births (Females, n=242)	10 (10.0)
	6 (2.5)
1	15 (6.2)
2	23 (9.5)
- 3	28 (11.6)
4	54 (22.3)
5 or more	116 (47.9)
	4

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian

Demographic and Health Survey (**Table 2b**).<sup>31</sup> Both groups had similar degrees of education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,<sup>32</sup> our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

# Table 2a: Income and household conditions

)
)
)
)
)
)
)
)
)

Water source		
	Pipe borne/boreholes	185 (53.5)
	Well	146 (42.2)
	River	15 (4.3)
Appliances		
	Electricity	318 (91.9)
	Television	262 (75.7)
	Radio	251 (72.5)
	Refrigerator	154 (44.5)
	Air conditioner	8 (2.3)
	Generating set	99 (28.6)
	Personal computer	38 (11.0)
	None	18 (5.2)

# Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

	NDHS Urban	NDHS Rural	NDHS Total	Current study (%)
<u> </u>	(%)	(%)	(%)	,
Cooking Fuel				
Electricity	0.7	0.2	0.4	10.7
Liquefied petroleum gas/natural	4.6	0.5	2.3	21.1
Gas/biogas				
Kerosene	47.6	8.7	25.5	31.8
Charcoal	5.3	1.6	3.2	2.3
Wood	37.9	83.3	63.7	34.1
Electricity				
Yes	83.6	34.4	55.6	91.9
No	16.3	65.4	44.2	8.1
Missing	0.1	0.2	0.2	0
Household Appliances		0.2	0.2	
Radio	77.7	61.3	68.3	72.5
Television	73.2	28.2	47.6	75.7
Refrigerator	32.5	7.5	18.3	44.5
Means of Transportation				
Bicycle	12.7	18.3	18.3	0.9
Motorcycle/scooter	27.0	31.2	31.2	15.0
Car/truck	14.4	8.7	8.7	12.1
Education	17.7	0.7	0.7	12.1
Lucation	NDHS	NDHS	Current	Current study
	Female	Male	study	Male
	(%)	(%)	Female	(%)
	(70)	(70)	(%)	(70)
No formal education	37.8	21.2	28.7	15.3
		16.7	26.8	25.9
Primary	17.3			
Secondary	35.8	47.7	28.0	22.4
More than secondary	9.1	14.3	16.5	36.5

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

> Within the group surveyed, cancer screening/assessment activities were limited: 2% (4/267) of female participants had a previous cervical smear/assessment, and 3% (6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was medi also infrequent.

Variable	n (%)
Cancer screening	
Cervical Cancer assessment	
(if female > 21, n = 261)	4 (1.5)
Previous mammogram (if	
female >40, n = 183)	6 (3.3)
Previous colonoscopy (if >50 years, n = 190)	9 (4.5)
Last primary health care physician	9 (4.5)
visit	
<1 year ago	180 (52.0)
1-4 years ago	93 (26.9)
5-10 years ago	32 (9.2)
>10 years ago	41 (11.8)
Last time seen traditional healer	
Never	254 (73.4)
<2 years ago	66 (19.1)
≥2 years ago	26 (7.5)
Hypertension	110 (31.8)
Diabetes	16 (4.6)
High cholesterol	24 (6.9)
Stroke	18 (5.2)
Alcohol use⁺	
No	227 (65.6)
Yes, drank in past, but quit	65 (18.8)
Yes, currently drink alcohol	54 (15.6)

Table 3: Screening activities,	access to medical services.	and health conditions

Smoking status*		
	Never	303 (87.6)
	Ever	43 (12.4)
Medication use		
Reported anti-hypertensive use		78 (22.5)
Reported aspirin use		89 (25.7)
Reported anti-cholesterol use	Reported anti-cholesterol use	
Reported herbal supplement use		233 (67.3)
Oral contraceptive use		
	Never	175 (67.0)
Past use		64 (24.5)
Curre	ent use	22 (8.4)

\* Participants were asked "Have you had 10 or more drinks of alcohol in your life?"

\* Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals, with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

#### Table 4: Insurance coverage and medical costs

2
3
4
5
6 7
/
8
9
10
11
12
13
15
14 15
15 16 17 18
16
17
18
10
19
20
21
22
23
24
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
25
26
27
28
29
30
21
31
32
33
34
35
36 37
37
57
38
38 39
40
41
42
43
44
45
46
47
48
49
49 50
51
52
53
54
55
50
57
58
59
60

1 2

Insurance	
N	331 (95.7)
Ye	s 15 (4.3)
Last time used insurance	
In the last 2 year	s 6 (40.0)
>2 years ag	9 (60.0)
How many family members covered by insurance	
Non	e 331 (95.7)
1-	2 8 (2.3)
3-	4 3 (0.9)
5 or more	e 4 (1.2)
Reasons for not having insurance (n=331)	
Expense	e 32 (9.7)
Lack of coverage	e 13 (3.9)
Too difficult to acces	s 73 (22.1)
Othe	r 217 (65.6)
Major medical costs in the last 2 years	
N	186 (53.8)
Ye	s 160 (46.2)
Estimated amount	
<10,000 Nair	a 73 (45.6)
10,000-49,000 Nair	a 38 (23.8)
50,000-99,999 Nair	a 16 (10.0)
>100,000 Nair	a 22 (13.8)
Unknow	n 11 (6.9)
Reasons for major medical costs (n=158)	
Surger	y 17 (10.8)
Chronic condition	s 52 (32.9)
Acute illness/traum	a 74 (46.8)
Other/multiple reason	s 15 (9.5)
Amount spent (continuous)	
Overall median (range	10,000 (50- ) 1,500,000)
Median amount spent by reason (range)	, 1,000,000)
incular anount opent by reason (range)	60,000 (7,000-
Surger	
Chronic condition	18,000 (500- s 150,000)
Acute illness/traum	. ,
	70,000 (800-
Other/multiple reason	

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education **Table 5**.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels of education. No significant relationship was observed by insurance status or other factors that were assessed (gender, marital Status, religion). In a multivariate logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

Table 5: Association between Ca	ncer	Screening Activ	vity and Incom	e, Insurance and
Education N =310 <sup>+</sup>				

Variable	Cancer Screening (N=17)	No Cancer Screening (N=293)	P value*	
Personal income (per month, in		, , , , , , , , , , , , , , , , , , ,		
Naira)				
<10,000	2/138 (1.5)	140/138 (98.5)		
10,000-49,999	9/122 (7.4)	115/122 (92.6)	<0.01	
>50,000	6/43 (14.0)	38/43 (86.0)		
Family income (per month, in				
Naira)				
<10,000	1/108 (0.9)	107/108 (99.1)		
10,000-49,999	8/129(6.2)	121/129(93.8)	<0.01	
>50,000	8/66 (12.1)	58/66 (87.9)		
Insurance Status				
No	15/290 (5.2)	275/290 (94.8)	0.40	
Yes	2/13 (15.4)	11/13 (84.6)	0.12	
Education				
No formal education	1/86 (1.2)	85/86 (98.8)		
Primary	3/83 (3.6)	80/83 (96.4)		
Secondary	8/78 (10.3)	70/78 (89.7)	0.04	
Higher	5/56 (8.9)	51/56 (91.1)		
-				
1			1	

No association by Gender, Marital Status, Religion

<sup>+</sup> Adjusted for eligible population, whereby cancer screening activities defined as history of cervical assessment in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years

\* Fisher's exact test for association

# DISCUSSION

 We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), <sup>6 19 33</sup> were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)<sup>31</sup> and likely represent broad health and development deficiencies present in the community.

Previous studies conducted in the region <sup>34-42</sup> have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.<sup>5 43</sup> This highlights a need to develop sound healthcare infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking through either delivery and/or uptake, and that the potential cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.<sup>35 36 44-47</sup> The Nigerian "National Cancer Control Plan 2018-2022,"

Page 23 of 34

#### **BMJ** Open

specifically details goals to make screening services and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.<sup>20</sup>. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022."<sup>20</sup> We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Whilst our analysis provides some idea of how individuals may have navigated the health system further detailed study is required to look at specific engagement at these different levels to inform appropriate resource allocation.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary alternative for early detection in low-resource settings.<sup>19 45 48</sup> This has been recommended in local policy and was not assessed in the current study.<sup>20</sup> Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer

screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.<sup>49</sup> Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.<sup>50 51</sup> Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.<sup>14 15</sup> Recent reports confirm that this expansion has been limited in Nigeria. In line with

#### **BMJ** Open

previous studies, our data indicate that the NHIS is severely underutilized in the community population.<sup>15 16</sup> The state health insurance scheme has been instituted in only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. <sup>15</sup>

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.<sup>16</sup> However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.<sup>52</sup> Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region <sup>53 54</sup>, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.<sup>35 42 44 55</sup> In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.<sup>56</sup> In addition, "demand-side"

approaches to resource allocation, such as the stipend we provided for travel in the study or e-vouchers,<sup>57 58</sup> are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated questionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. Whilst we have documented low levels of screening activities and associations with income and education, we did not directly require individuals to state specifically their personal reasons for not being screened to delineate availability, awareness or finances. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition (e.g., resulted in more females than males). Nevertheless, overall consistency with national demographic indicators (e.g., income, education, and living conditions) indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.<sup>31 32</sup>

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this,

 including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

For peer teriew only

# Ethical Approval Statement

The study was approved by the Obafemi Awolowo University institutional ethics review committee. Further details available directly from: Obafemi Awolowo University Teaching Hospitals Complex, ILE-IFE, NIGERIA. Ethics and Research Committee

Mr. M.O. Adeyeye,

Head.Clinical Services and Training,

OAUTHC, lle-lfe. 08032430923

Or

Ms. B. A. Ayoola 08068810690

Desk Officer, Ethics and Research Committee

Reversion of the second

# REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. BMJ Case Reports 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- 12. Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. *Bull World Health Organ* 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

4

5

6 7

8

9

10

11

12 13

14

15

16

17

18 19

20

21

22

23 24

25

26

27

28 29

30

31

32

33

34 35

36

37

38

39

40 41

42

43

44

45 46

47

48

49

50

51 52

53

54

55

56 57

58

- Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- 15. Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. *Int J Health Policy Manag* 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- 22. Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

*journal of public health* 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. REPRODUCIBILITY AND VALIDITY OF A SEMIQUANTITATIVE FOOD FREQUENCY QUESTIONNAIRE. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. *Eur J Cancer Care (Engl)* 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 35. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. *Cancer Causes & Control* 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- 36. Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. *Journal of Global Oncology* 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 37. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
   [published Online First: 2016/12/30]
- 38. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]
- Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. Asian Pac J Cancer Prev 2010;11(1):137-40. [published Online First: 2010/07/03]
- 40. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 41. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]

- 42. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 43. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- 44. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- 45. Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- 46. Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 47. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- 49. Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 50. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 51. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. World J Surg 2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]
- 52. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 53. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 54. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and

2	
3	
4	
5	
6 7	
/	
8	
9	
10	
11	
12	
13	
12 13 14 15 16 17	
15	
16	
10	
17	
18	
19	
20	
21	
22	
23	
24	
25	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
54 55	
56	
57	
58	

59 60 out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: <u>https://doi.org/10.1016/S0140-6736(17)30874-7</u>

- 55. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 56. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. JMIR Mhealth Uhealth 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 57. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 58. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

1	
2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22 23	
24	
25	
26	
27	
28	
29	
30	
50	
31	
32	
33	
34	
35	
36	
37	
27	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52 53	
54	
55	
56	
57	
58	
59	
60	

STROBE Statement—Checklist of items that should b	be included in reports of <i>cross-sectional studies</i>
	-

Item No	Recommendation	Page No
1	( <i>a</i> ) Indicate the study's design with a commonly used term in the title	4
	or the abstract	
	(b) Provide in the abstract an informative and balanced summary of	4
	what was done and what was found	
2	Explain the scientific background and rationale for the investigation	8,9
		,
3	State specific objectives, including any prespecified hypotheses	9
4	Present key elements of study design early in the paper	10,11
		10
,		10
6		10
0		10
7		10
,		10
8*		11
0		
9		10,11
		10
		11
12		12,13
		,
		12,13
		13
		n/a
		n/a
		1
13*	(a) Report numbers of individuals at each stage of study—eg numbers	13
15		15
		13
		n/a
14*		13,14
17		13,17
		n/a
		11/ U
15*	Report numbers of outcome events or summary measures	14,15,1
	No           1           1           2           3           4           5           6           7           8*           9           10           11           12           13*           14*	No         Recommendation           1         (a) Indicate the study's design with a commonly used term in the title or the abstract           (b) Provide in the abstract an informative and balanced summary of what was done and what was found           2         Explain the scientific background and rationale for the investigation being reported           3         State specific objectives, including any prespecified hypotheses           4         Present key elements of study design early in the paper           5         Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection           6         (a) Give the eligibility criteria, and the sources and methods of selection of participants           7         Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable           8*         For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group           9         Describe any efforts to address potential sources of bias           10         Explain how the study size was arrived at           11         Explain how missing data were addressed (d) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) Give theasent for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each s

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	15,16
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	n/a
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	n/a
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and	n/a
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	21
Limitations	19	Discuss limitations of the study, taking into account sources of	21-25
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	21-25
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	21-25
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	1
		study and, if applicable, for the original study on which the present	
		article is based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

# **BMJ Open**

# Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-040352.R2
Article Type:	Original research
Date Submitted by the Author:	28-Jun-2021
Complete List of Authors:	Sharma, Avinash; Memorial Sloan Kettering Cancer Center, Surgery Alatise, Olusegun; Obafemi Awolowo University Teaching Hospital Complex O'Connell, Kelli; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Gbenga, Ogunleye; Obafemi Awolowo University Teaching Hospital Complex, Surgery Aderounmu, Adewale; Obafemi Awolowo University Teaching Hospital Complex, Surgery Samson, Marquerite; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics Wuraola, Funmilola; Obafemi Awolowo University Teaching Hospital Complex Olasehinde, Olalekan; Obafemi Awolowo University Teaching Hospital Complex Kingham, T; Memorial Sloan Kettering Cancer Center, Surgery Du, Mengmeng; Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics
<b>Primary Subject Heading</b> :	Global health
Secondary Subject Heading:	Oncology, Health services research, Public health
Keywords:	PUBLIC HEALTH, PREVENTIVE MEDICINE, Epidemiology < ONCOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

Healthcare utilization, cancer screening and potential barriers to accessing cancer care in Rural South-West Nigeria: A cross-sectional study.

Sharma A. MD<sup>1</sup>, Alatise O. I. MBChB<sup>2</sup>, O'Connell K. MSc<sup>3</sup>, Ogunleye S.G. MSc<sup>2</sup>, Aderounmu A.A. MBChB<sup>2</sup>, Samson. M.L. BSc<sup>3</sup>, Wuraola F. MBChB<sup>2</sup>, Olasehinde O. MBChB, Kingham T.P MD<sup>1</sup>, Du M. ScD<sup>3</sup>

<sup>1</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Obafemi Awolowo University, Ile-Ife, Nigeria; <sup>3</sup>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. African Research Group for Oncology (ARGO).

**Acknowledgments:** The authors would like to acknowledge the dedicated research team at OAUTHC for their efforts in this project, the local community leaders and healthcare workers, as well as the support from Prof. Adesgun Fatusi and his research staff.

# **Correspondence:**

Avinash Sharma

Memorial Sloan Kettering Cancer Center

1275 York Avenue, C-886

New York, NY 10065

avinash.s.sharma@gmail.com

## ABSTRACT

**Background/Aims:** Cancer burden is predicted to double by 2030 in sub-Saharan Africa; access to healthcare services for cancer management is a priority in the region. In Nigeria, National Cancer Control Plan aims to ensure >50% cancer screening of eligible populations by 2022 for all Nigerians. We describe healthcare utilization, cancer screening activities and potential barriers to accessing cancer care within an understudied rural community-based adult population in South-West Nigeria.

**Methods:** In April 2018, we conducted a cross-sectional study of community-based adults (>18 years) ~130 kilometres east of Ibadan, 250 km from Lagos in Osun State, South-West Nigeria. Participants completed a face-to-face survey in local dialect. We used a questionnaire to assess demographics, health status, income, medical expenditures, doctor visits, and cancer screening history.

**Results:** We enrolled 346 individuals; with median age of 52 years, and 75% female. Of the entire cohort, 4% had medical insurance. 46% reported a major medical cost in the last year. Cancer screening activities were infrequent in eligible participants: 1.5% reported having had cervical cancer screening, 3.3% mammogram, and 5% colonoscopy screening. Cancer screening assessment was less frequent in those with less income and lower education levels. Using a multivariable logistic regression model including personal income, insurance status, and education, higher personal income was associated with more cancer screening activity (OR 2.7 95%CI 1.3-5.7 p<0.01). Despite this, most individuals had contact with a primary health care doctor (52% in the last year), and over 70% access to radio and TV suggesting the opportunity to expand community-based screening interventions and awareness exists.

**Conclusions:** Despite national increases in cancer cases, we highlight a deficiency in cancer screening and universal healthcare coverage within a community-based adult Nigerian population. Subject to availability of governmental resources, increasing financial risk protection, awareness, and targeted resource allocation may help expand access in Nigeria.

Keywords: Non-communicable disease, Sub-Saharan Africa, Cancer, Universal Healthcare, Screening

## Strengths and Limitations of the study:

- 1) Rigorously trained interviewers fluent in the local dialect collected contemporary perspectives of potential barriers to accessing medical and cancer care in a crucially understudied population in rural South-West Nigeria.
- Questionnaire items derived by adapting features from validated and/or widely implemented local or nationwide surveys and tailored to the local population in collaboration with local clinicians, epidemiologists, and nutritionists.
- Study conducted in conjunction with local community healthcare workers and the regional tertiary referral hospital to help build capacity, increase healthcare awareness, and establish a sustained relationship with these rural communities.

- 4) Potential for measurement error or recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services.
  - 5) Survey conducted at a single time (mid-week, during the day) in two geographic locations, which may have affected sample composition (e.g., more females than males).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## INTRODUCTION

The burden of non-communicable disease (NCD), in particular cancer, in sub-Saharan Africa is well documented.<sup>1-3</sup> According to recent International Agency for Research on Cancer GLOBOCAN estimates, by 2030, 75% of new cancer cases will be within low and middle-income countries.<sup>4 5</sup> In sub-Saharan Africa, despite the fact that cancer burden is predicted to double by 2030, the entire region accounts for <1% of worldwide medical cancer expenditures.<sup>6-8</sup> Central to addressing the growing burden of cancer in sub-Saharan Africa is the need to improve access to cancer care services for screening, prevention, and treatment.<sup>9</sup>

NCDs, including cancer, threaten to overwhelm fragile health systems in sub-Saharan Africa and lead to dramatic rises in health and social care costs in the near-term.<sup>7 10</sup> In the region, out-of-pocket health expenditures are a major contributor to poverty <sup>11-</sup><sup>13</sup>, and a lack of adequate social protection has the potential to drive families and individuals further into poverty. In Nigeria, universal healthcare coverage in the form of the National Health Insurance Scheme (NHIS) was implemented in 2005, with an overarching goal of universal health coverage for all Nigerians.<sup>14</sup> However, uptake has been limited and restricted,<sup>15</sup> and as a result, the large majority of Nigerians still face significant financial burden when healthcare needs arise.<sup>15 16</sup>

In Nigeria cancer incidence and mortality is increasing and women have a higher cancer incidence than men.<sup>17</sup> The most common forms of cancer in Nigeria are breast and cervical, with these accounting for over 50 percent of cancer deaths.<sup>17-19</sup> Regionally, the need to improve access to cancer services for early detection has been recognised, with a focus on these cancers. In 2018, Nigeria launched the "National

Page 7 of 45

#### **BMJ** Open

Cancer Control Plan 2018-2022," with the goal to make screening services available for all Nigerians, and at least "greater than 50% screening of all eligible populations by 2022."<sup>20</sup> Despite this, the current state of cancer screening activities and barriers to care in this region (esp. rural areas) are not well-defined or documented. This gap limits our ability to define actionable steps towards improving access and achieving the established screening goal. National programmes for screening breast and cervical cancer are lacking. Typically, screening interactions occur at primary health care facilities or community health clinics – often for women when they are being seen during pregnancy or for other related health issues such as immunisations. Screening services for cervical and breast cancer have been implemented sporadically by both government and non-government organisations but predominantly in urban areas. The overwhelming majority of individuals in the region are symptomatic when they present with disease. With 50 percent of Nigeria's population living in rural areas<sup>21</sup> we hypothesize that unique challenges may exist for individuals in these communities, where nationwide initiatives may have limited reach.

This study aimed to describe potential barriers to accessing cancer care within a rural community-based adult population in South-West Nigeria. This study was performed as part of a broader community-based capacity building project in South-West Nigeria<sup>22</sup> investigating potentially modifiable cancer risk factors in the setting of rising rates of cancer in the region.<sup>6</sup> <sup>19</sup> <sup>20</sup> <sup>23</sup> Herein, we report health insurance coverage and socioeconomic status in relation to health conditions, health expenditures, cancer screening assessment and provide a snapshot of the health needs and burden faced by individuals in the region.

## **METHODS**

During April 2018, a cross-sectional study of community-based adults was conducted in Osun State, South-West Nigeria. Two rural towns ljebu-Jesa and Ere-Jesa, (approximately 130 kilometers east of Ibadan, 250 km from Lagos, on latitude 7.45 degrees north within the rain forest belt), were selected at random. These towns were in proximity to Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, the main tertiary referral center in the region. This study was part of a broader capacity building project in the region to improve cancer care and prevention in this understudied population. It served as a baseline study to assess access to cancer services as well as a pilot study to explore endemic risk factors for cancer – such as unique dietary, exercise and environmental exposures.

## Patient and Public Involvement

Prior to the study, local community leaders in the towns were contacted, and the goals of the research were explained. In the time leading up to the study, healthcare workers and community leaders notified and mobilized all potential participants in the two communities. They were also involved in the design of the study and in disseminating the results to all participants. Participants were notified of the study through discussion at the weekly local community meetings in the month leading up to the study, advertisements on local radio-stations and through community workers visiting regional sites.

## Participants

#### **BMJ** Open

Adults >18 years in the two towns were invited to participate. Adult participants were consecutively enrolled upon arrival at pre-designated locations (main town hall) in the two towns. Sample size for this study was therefore based on resource capacity of each town hall, available number of interviewers to administer the questionnaire, and the size of each rural community in which we recruited; enrolment was capped at a maximum of 300 participants at Ijebu-Jesa and 100 at Ere-Jesa over the recruitment period. All study participants received blood pressure checks, and health promotion talks were held for those waiting to be surveyed. Study participants were given a small stipend to cover their transportation costs to the study venue on the study day (300 Naira, ~80 US cents). This amount was determined by local healthcare workers.

## Questionnaire

The survey consisted of a questionnaire to gather quantitative data on demographics, health status, income, medical expenditures, dietary habits, physical activity, family history, screening history, medical history, reproductive history, primary healthcare visits, medication use, and environmental exposures. (See supplementary file). The questionnaire used was developed in collaboration with local clinicians, epidemiologists, and nutritionists, and was derived by adapting features from validated and/or widely implemented local or nationwide surveys. This included the Nigeria Demographic and Health Survey,<sup>24</sup> Nigeria General Household Survey,<sup>25</sup> World Health Organization-endorsed Global Physical Activity Questionnaire,<sup>26</sup> and the Nurses' Health Study questionnaire.<sup>27-30</sup> We therefore did not additionally test for reliability and our study was intended to capture a cross-sectional snapshot of our rural communities. However, we expect low social mobility in our two rural Nigerian towns

and therefore limited changes over time for the sociodemographic features collected in our questionnaire.

#### Data collection

After obtaining informed consent, the study participants underwent a 50-60 minute one-on-one, face-to-face survey conducted in the local Yoruba dialect by a trained research assistant. All research assistants underwent a two-day training program that involved education into the research aims, methodology, and ethics as well as interview techniques through role paying exercises, pilot testing of the questionnaire and the use of electronic tablets for recording data.

#### Outcome measures

Cancer screening activities in screen-eligible individuals included history of cervical examination and screening test in women >21 years, mammogram in women >40 years, and colonoscopy in all individuals >50 years. Because cervical cancer screening intervention was self-reported, screening could be by pap smear or visual inspection with acetic acid or Lugo's iodine (VIA/VILI). This could be conducted in a primary healthcare setting. Manual breast examination by a health care worker was not captured and therefore the assessed intervention evaluated management at local secondary and tertiary health care facilities. All of the assessed interventions were screening activities specified as part of the Nigerian National Cancer Control Plan 2018-2022. Medical expenses were defined as any 'major medical costs' as perceived by the study participant on direct questioning. This was clarified by recording the amount spent in Naira, and the medical reason for the expenditure was also documented. Demographic and socioeconomic data collected from our study

**BMJ** Open

population were compared to data from the Nigerian Demographic and Health Survey and the Oxford Poverty Health Indicator <sup>31 32</sup> to assess external validity.

## Statistical analysis

Data were summarized in the form of proportions and frequency tables for categorical variables. Continuous variables were summarized using mean, median, and standard deviation. Comparisons of discrete variables were computed using Fisher's exact test and multiple logistic regression. Missing data were not possible for completed questionnaires as only complete responses to questions could be processed in order to advance the survey on the electronic tablets. All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC)

(elie

## RESULTS

A total of 346 individuals were consecutively enrolled in the study and interviewed during the recruitment period. All individuals that were interviewed provided data for analysis. The demographic features of the group are presented in **Table 1**. The majority of participants were Yoruba speaking (n=332, 96%) and married (n=213, 62%) with a median age of 52 years. Females accounted for 75% of the cohort (n=261). Most individuals had some form of education, with 166 participants (48%) reporting more than primary school education. In addition, 30 participants (9%) reported being unemployed. Of female participants, 70% had ≥4 live births.

#### Table 1: Demographic characteristics of the study group (n=346)

(n=268 ljebu-Jesa, n=68 Ere-Jesa)

Variable	n (%)
Median Age, years (range)	52 (18-100
Sex	
Ma	e 85 (24.6)
Fema	e 261 (75.4)
Marital Status	
Sing	e 27 (7.8)
Marrie	d 213 (61.6)
Other (Divorced/cohabiting	g) 106 (30.6)
Tribe	
Yorut	a 332 (96.0)
It	o 5 (1.4)
Oth	er 9 (2.6)
Religion	
Christia	,
Musli	, ,
Oth	er 1 (0.3)
Education	
No formal education	, ,
Prima	
Seconda	. ,
Vocational/Technic	· · · ·
High	er 29 (8.4)
Occupation	•
Unemploye	
Civil serva	
Trad	
Farm	
Self-employe	
Oth	er 48 (13.9)
Number of Live Births (Females, n=242)	
	0 6 (2.5)
	1 15 (6.2)
	2 23 (9.5)
	3 28 (11.6)
_	4 54 (22.3)
5 or mo	re   116 (47.9)

Overall, 155 participants (45%) had a personal monthly income of <10,000 Naira (~1 USD per day), and 134 individuals (76%) had a family monthly income of <50,000 Naira (140 USD per month) (**Table 2a**). In addition, 198 participants (57%) lived in a

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

family home or owned an apartment. The majority of participants (92%) reported having access to electricity, and over 70% reported access to television (76%) or radio (73%).

To assess the comparability of our results to the general Nigerian population, we compared the data from our study population to that recorded in the Nigerian Demographic and Health Survey (**Table 2b**).<sup>31</sup> Both groups had similar degrees of education at the primary level for males and females, but overall there were fewer uneducated males and females within our surveyed population when compared to national averages. Our surveyed group also had better access to electricity, radio, and television compared to the national survey group (rural). When compared to equivalent parameters for Nigeria from the multi-dimensional poverty index (MPI) developed by the Oxford Poverty and Human Development Initiative,<sup>32</sup> our study population had similar levels of deprivation for years of schooling (defined as <6 years of school) and electricity (defined as no household electricity).

## Table 2a: Income and household conditions

n (%)
155 (44.8)
139 (40.2)
26 (7.5)
16 (4.6)
9 (2.6)
1 (0.3)
117 (33.8)
147 (42.5)
38 (11.0)
28 (8.1)
11 (3.2)
5 (1.4)

.

3
4
4 5
6
7
8
9
10
11
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
~~
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
59 60

60

1 2

Type of dwelling	
Own apartment	131 (37.9
Rent apartment	146 (42.2
Family house	67 (19.4
Other	2 (0.6)
Type of toilet	
Water system	151 (43.0
Pit latrine	164 (47.4
Bush	23 (6.6)
Bucket	7 (2.0)
Other	1 (0.3)
Water source	
Pipe borne/boreholes	185 (53.
Well	146 (42.
River	15 (4.3
Appliances	
Electricity	318 (91.
Television	262 (75.
Radio	251 (72.
Refrigerator	154 (44.
Air conditioner	8 (2.3)
Generating set	99 (28.6
Personal computer	38 (11.0
None	18 (5.2)

# Table 2b: Comparison between study sample characteristics and 2013 Nigerian National Demographic and Health Survey (NDHS)

	NDHS Urban (%)	NDHS Rural (%)	NDHS Total (%)	Current study (%)
Cooking Fuel				
Electricity	0.7	0.2	0.4	10.7
Liquefied petroleum gas/natural Gas/biogas	4.6	0.5	2.3	21.1
Kerosene	47.6	8.7	25.5	31.8
Charcoal	5.3	1.6	3.2	2.3
Wood	37.9	83.3	63.7	34.1
Electricity				
Yes	83.6	34.4	55.6	91.9
No	16.3	65.4	44.2	8.1
Missing	0.1	0.2	0.2	0
Household Appliances				
Radio	77.7	61.3	68.3	72.5
Television	73.2	28.2	47.6	75.7
Refrigerator	32.5	7.5	18.3	44.5
Means of Transportation				
Bicycle	12.7	18.3	18.3	0.9
Motorcycle/scooter	27.0	31.2	31.2	15.0
Car/truck	14.4	8.7	8.7	12.1

Education				
	NDHS Female (%)	NDHS Male (%)	Current study Female	Current study Male (%)
			(%)	
No formal education	37.8	21.2	28.7	15.3
Primary	17.3	16.7	26.8	25.9
Secondary	35.8	47.7	28.0	22.4
More than secondary	9.1	14.3	16.5	36.5
,				

Within the group surveyed, cancer screening/assessment activities were limited: 2% (4/267) of female participants had a previous cervical smear/assessment, and 3% (6/182) of females >40 years had ever had a mammogram (**Table 3**). The prevalence of colonoscopy screening in those >50 years was 5% (9/200). In terms of healthcare access, 180 individuals (52%) had seen a primary healthcare doctor in the last year and were less likely to see a traditional healer during this period. Of all participants, 110 reported being diagnosed with hypertension (32%), but most individuals were not on daily hypertensive medication (n=324, 94%). The use of other medications for primary prevention of NCDs, such as aspirin and anti-cholesterol medications, was also infrequent.

Variable	n (%)
Cancer screening	
Cervical Cancer assessment	
(if female > 21, n = 261)	4 (1.5)
Previous mammogram (if	
female >40, n = 183)	6 (3.3)
Previous colonoscopy (if >50	
years, n = 190)	9 (4.5)
Last primary health care physician	
visit	
<1 year ago	180 (52.0)
1-4 years ago	93 (26.9)
5-10 years ago	32 (9.2)
>10 years ago	41 (11.8)
Last time seen traditional healer	

## Table 3: Screening activities, access to medical services, and health conditions

Never	254 (73.4)
<2 years ago	66 (19.1)
≥2 years ago	26 (7.5)
Hypertension	110 (31.8)
Diabetes	16 (4.6)
High cholesterol	24 (6.9)
Stroke	18 (5.2)
Alcohol use⁺	
No	227 (65.6)
Yes, drank in past, but quit	65 (18.8)
Yes, currently drink alcohol	54 (15.6)
Smoking status*	
Never	303 (87.6)
Ever	43 (12.4)
Medication use	
Reported anti-hypertensive use	78 (22.5)
Reported aspirin use	89 (25.7)
Reported anti-cholesterol use	7 (2.0)
Reported herbal supplement use	233 (67.3)
Oral contraceptive use	
Never	175 (67.0)
Past use	64 (24.5)
Past use Current use	64 (24.5) 22 (8.4)

 \* Participants were asked "Have you had 10 or more drinks of alcohol in your life?"

\* Participants were asked "Have you smoked 5 packs of cigarettes (100) or more in your lifetime?"

Only 15 individuals out of 346 (4%) had medical insurance (**Table 4**). For the remaining uninsured participants, 66% reported that they were unaware that health insurance existed. A further 73 participants (22%) stated that insurance was too difficult to access. Despite this, nearly half of those surveyed (n=160, 46%) reported a major medical cost in the last year, with the majority from unforeseen events, such as acute illness, trauma, or surgery (58%). The costs incurred ranged from 5000-1,500,000 Naira, with a median of 10,000 Naira, an amount that is more than the monthly income for ~45% of individuals in this study. In addition, 52 participants (33%) reported that their major medical costs were for chronic conditions. Overall individuals,

 **BMJ** Open

with incomes in the lowest brackets (<50,000 Naira), accounted for most of those that incurred major medical costs in the last two years (74.4%), had more visits to their primary care doctor in the year (75.6%), and higher levels of hypertension (80.4%).

## Table 4: Insurance coverage and medical costs

Variable		n (%)
Insurance		
	No	331 (95.7)
	Yes	15 (4.3)
Last time used insurance		
In the last	2 years	6 (40.0)
>2 ye	ears ago	9 (60.0)
How many family members covered by insu	rance	
	None	331 (95.7)
	1-2	8 (2.3)
	3-4	3 (0.9)
5	or more	4 (1.2)
Reasons for not having insurance (n=331)	4	
E	Expense	32 (9.7)
Lack of c	overage	13 (3.9)
Too difficult to	access	73 (22.1)
	Other	217 (65.6)
Major medical costs in the last 2 years		
	No	186 (53.8)
	Yes	160 (46.2)
Estimated amount		
<10,00	00 Naira	73 (45.6)
10,000-49,00	00 Naira	38 (23.8)
50,000-99,99	99 Naira	16 (10.0)
>100,00	00 Naira	22 (13.8)
U	Inknown	11 (6.9)
Reasons for major medical costs (n=158)		
	Surgery	17 (10.8)
Chronic co	onditions	52 (32.9)
Acute illness	s/trauma	74 (46.8)
Other/multiple	reasons	15 (9.5)
Amount spent (continuous)		
Overall median	(range)	10,000 (50- 1,500,000)
Median amount spent by reason (range)	(iaiiye)	1,500,000)
median amount spent by reason (range)		60,000 (7,000-
	Surgery	150,000)
	nditions	18,000 (500-
Chronic co	maitions	150,000)

**BMJ** Open

Acute illness/trauma 5,000 (50-400,000) Other/multiple reasons

70,000 (800-

500,000)

Within eligible populations, we performed analysis to look for the association between cancer screening activity and income, insurance status and education Table 5. Individuals with lower levels of income were less likely to have had cancer screening assessments. Cancer screening activity was more frequent in those with higher levels of education. No significant relationship was observed by insurance status or other factors that were assessed. In a multivariable logistic regression model including personal income, insurance status and education, the only statistically significant odds ratio for association with cancer screening activity was observed for personal income (personal income OR 2.7 95%CI 1.3-5.7 p<0.01, education level OR 1.7 95%CI 0.98-2.7 p=0.06, insurance status OR 4.3 95%CI 0.8-23.1 p=0.09.

Cancer Screening (N=17)	No Cancer Screening (N=293)	P value*
2/138 (1.5)	140/138 (98.5)	
9/122 (7.4)	115/122 (92.6)	<0.01
6/43 (14.0)	38/43 (86.0)	
1/108 (0.9)	107/108 (99.1)	
8/129(6.2)	121/129(93.8)	<0.01
8/66 (12.1)	58/66 (87.9)	
15/290 (5.2)	275/290 (94.8)	0.12
2/13 (15.4)	11/13 (84.6)	0.12
1/86 (1.2)	85/86 (98.8)	
3/83 (3.6)	80/83 (96.4)	0.04
8/78 (10.3)	70/78 (89.7)	
	(N=17) 2/138 (1.5) 9/122 (7.4) 6/43 (14.0) 1/108 (0.9) 8/129(6.2) 8/66 (12.1) 15/290 (5.2) 2/13 (15.4) 1/86 (1.2) 3/83 (3.6)	(N=17) $(N=293)$ $2/138$ (1.5) $140/138$ (98.5) $9/122$ (7.4) $115/122$ (92.6) $6/43$ (14.0) $38/43$ (86.0) $1/108$ (0.9) $107/108$ (99.1) $8/129(6.2)$ $121/129(93.8)$ $8/66$ (12.1) $58/66$ (87.9) $15/290$ (5.2) $275/290$ (94.8) $2/13$ (15.4) $11/13$ (84.6) $1/86$ (1.2) $85/86$ (98.8) $3/83$ (3.6) $80/83$ (96.4)

Table 5: Association between Cancer Screening	Activity	and Income	, Insurance and
Education N =310 <sup>+</sup>			

1				
2 3	Higher	5/56 (8.9)	51/56 (91.1)	
4 5	righti	0/00 (0.0)	01/00 (01.1)	
6 7	No association by Gender, Marital Status, Religion	' I	'	·
8	* Adjusted for eligible population, whereby cancer		tory of cervical assessment in wome	n >21 years,
9 10	mammogram in women >40 years, and colonosco * Fisher's exact test for association	py in all individuals >50 years		
11 12				
13				
14 15				
16 17				
18				
19 20				
21 22				
23				
24 25				
26 27				
28				
29 30				
31 32				
33				
34 35				
36 37				
38				
39 40				
41 42				
43				
44 45				
46 47				
48				
49 50				
51 52				
53				
54 55				
56 57				
58				
59 60				

## DISCUSSION

We performed a cross-sectional community-based study in Osun state, Nigeria to provide a snapshot of the challenges faced in the management of NCDs in the region. This study was conducted with an emphasis on cancer within broader research aims of identifying risk factors (lifestyle, diet, biological) associated with the rising cancer incidence in the region. We observed that screening assessment for breast, cervical, and colon cancer (the major contributors to cancer morbidity in the region), <sup>6 19 33</sup> were extremely low. This observation was despite a median age of 52 years and a high representation of females. In addition, <5% of the surveyed population possessed universal health care in the form of health insurance. We also found low incomes, high fertility rates, and evidence of poorly controlled chronic diseases, such as hypertension, in our cohort. The rates are comparable to national averages (suggesting our sample sits between the urban/rural divide)<sup>31</sup> and likely represent broad health and development deficiencies present in the community. For example, the high prevalence of hypertension in this population is remarkably similar to that reported in a systematic review and meta-analysis conducted in the region.<sup>34 35</sup> The high burden of hypertension in the region has also been recently acknowledged by the World Health Organization in its efforts to control hypertension in Nigeria.<sup>36</sup>

Previous studies conducted in the region <sup>37-45</sup> have demonstrated that poor access to cancer services is associated with late presentation and high incidence/mortality ratio.<sup>5 46</sup> This highlights a need to develop sound healthcare infrastructure, whereby individuals can be screened for asymptomatic disease and also adequately access services in a timely fashion when symptomatic. Our study identifies that screening activities may be lacking through either delivery and/or uptake, and that the potential

Page 21 of 45

#### **BMJ** Open

cost implications of accessing treatment when symptoms arise, in the absence of adequate health insurance, can be high. The experience from other sub-Saharan African nations suggests that individuals seeking cancer services face significant barriers to access.<sup>38 39 47-50</sup> The Nigerian "National Cancer Control Plan 2018-2022," specifically details goals to make screening services and early detection of cancer available for all Nigerians, and to improve access to quality, cost-effective, and equitable diagnostic and treatment services for cancer care. This is centered around investment in eight public comprehensive cancer centers covering all geo-political zones, as well as the implementation of various screening strategies throughout different sectors of the healthsystem.<sup>20</sup>. Our results suggest that considerable work is required to reach the goal of "greater than 50% screening of 'eligible populations' by 2022.<sup>20</sup> We assessed cancer screening using measures that are recommended in this national plan. The methods we assessed are accessed at different levels of the healthcare system – cervical cancer assessment predominantly at a primary health care level, breast cancer at secondary/tertiary level through mammography, and colon cancer at tertiary level through colonoscopy. Whilst our analysis provides some idea of how individuals may have navigated the health system further detailed study is required to look at specific engagement at these different levels to inform appropriate resource allocation.

It is important to acknowledge that cancer screening in low and middle income countries requires measures tailored to local capacity and disease prevalence. For breast cancer, although mammography remains the gold standard for early detection of breast cancer, the Breast Health Global Initiative (BHGI) resource-stratified guidelines recommend clinical breast examination as a practical and necessary

alternative for early detection in low-resource settings.<sup>19 48 51</sup> This has been recommended in local policy and was not assessed in the current study.<sup>20</sup> Despite this, with over 50 percent of individuals in this study visiting a primary health care doctor in the last year, our findings strongly support the need to concentrate cancer screening efforts at primary healthcare where possible through the use of similar interventions. Colon cancer screening by colonoscopy for those over the age of fifty as recommended in high income countries does not exist in sufficient capacity for this to be recommended in an LMIC setting.<sup>52</sup> Efforts to intervene at primary healthcare level through the use of stool testing and symptom stratification are ongoing.<sup>53 54</sup> Overall, education, training and adequately resourcing community healthcare workers and physicians at primary healthcare level for cancer screening assessment is essential.

We demonstrated that both income and medical expenditure relative to this level of income, compounded by the lack of universal health care coverage, must be factored into strategies laid out to address cancer control. The costs of the screening interventions assessed in this study relative to income, are prohibitive for the majority of individuals without government subsidy; approx. \$50 US ~ \$18000 Naira (for mammography), \$15 US ~ \$3000 Naira (cervical smear). This is compounded by the finding of only 4% of our cohort having health insurance coverage. In addition, major medical costs were incurred by over half of those interviewed, and a significant proportion of these costs were for chronic diseases (33%). Those individuals with the lowest income were more likely to report visits to the doctor, chronic disease, and significant "out of pocket" medical expenditures. The Nigerian national health insurance scheme (NHIS) has been in place since 2005. When it was introduced, state

Page 23 of 45

#### **BMJ** Open

governments were instructed to adopt the program for their employees in the formal sector. After insuring government employees, state governments were instructed to expand coverage across all individuals with the goal of universal health coverage.<sup>14 15</sup> Recent reports confirm that this expansion has been limited in Nigeria. In line with previous studies, our data indicate that the NHIS is severely underutilized in the community population.<sup>15 16</sup> The state health insurance scheme has been instituted in only 2 out of 36 states of the federation at community level and this has not been the case in Osun state where the study took place. <sup>15</sup>

We found wide range of "major" medical expenditure in our study group, with a median expenditure exceeding the monthly salary of ~45% of the group. It is important to note that we did not obtain information on total household expenditures to allow a relative assessment of the amount spent on medical costs, and, in turn, determine "catastrophic" costs.<sup>16</sup> However, based on income and demographic comparisons with other groups studied in the region, it is likely that catastrophic spending is high.<sup>55</sup> Further research into how the money to cover medical expenditure is generated (i.e., personal savings, family savings, loans, etc.) is required. Taken together with prior work in the region <sup>56 57</sup>, it is evident that risk pooling and financial risk protection are required for the provision of preventative and therapeutic NCD health services.

Whilst we did not directly assess awareness of cancer screening, we did demonstrate an association between cancer screening activity and education level. Levels of education have been associated with awareness and accessing cancer services in previous studies.<sup>38 45 47 58</sup> In addition to this, we also found that ~75% of participants had access to radio and/or television within family and social networks, suggesting

#### **BMJ** Open

that mass communication channels to promote health awareness exist. In fact, these facilitated the current study when combined with strategies using mobile phone technologies. More broadly, these channels represent promising avenues to promote health and prevention of disease in the region.<sup>59</sup> In addition, "demand-side" approaches to resource allocation, such as the stipend we provided for travel in the study or e-vouchers,<sup>60 61</sup> are likely to be well received by the community and may promote uptake of health-screening activities.

A strength of this study is that it was performed within the community and involved trained research staff fluent in the local dialect and used a validated questionnaire. The study was performed in conjunction with local community healthcare workers and the tertiary referral hospital, which was intended to help residents develop an awareness of how and where healthcare can be accessed in the area and to establish a sustained relationship with this community. Limitations of this work include the potential for misclassification and recall bias, as we relied on individuals to retrospectively describe their own health and socioeconomic status as well as their interactions with healthcare services. Whilst we have documented low levels of screening activities and associations with income and education, we did not directly require individuals to state specifically their personal reasons for not being screened; we were therefore unable to delineate specific barriers to cancer screening, such as emotional barriers (e.g., concern about cancer diagnosis, limited awareness) and barriers to access (e.g., screening locations, availability of transportation, limited finances, etc.). Detailed qualitative analysis of these barriers would be worthwhile and is the subject of our future work in the region. In addition, while the study sample was chosen at random and consecutive individuals were enrolled, the survey was

#### **BMJ** Open

conducted at a single time that was mid-week, during the day; this timing may have affected our sample composition. For instance, 75% of participants in our study were female, which may potentially limit the generalizability of our findings. However, it is reassuring we observed overall consistency with national demographic indicators (e.g., income, education, and living conditions), which indicates that our sample is likely reflective of rural community-dwelling individuals in the wider region.<sup>31 32</sup>

In summary, our results highlight infrequent cancer screening activities in a Nigerian community population and identifies areas that can be targeted to address this, including the use of measures focused at primary healthcare level, financial risk protection, awareness, and strategic resource allocation.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

## **Ethical Approval Statement**

The study was approved by the Obafemi Awolowo University institutional ethics review committee.

# Author contributions:

#### 1. Avinash Sharma

Author contributions: Initial conception, study and questionnaire design, data collection, data analysis, manuscript writing

#### 2. O.I. Alatise

Author contribution: Initial conception, study and questionnaire design, manuscript revision

#### 3. K. O'Connell

Author contributions: Data and statistical analysis, questionnaire design, manuscript revision

#### 4. S.G Ogunleye

Author contributions: study organisation, data collection, manuscript revision

#### 5. A.A. Aderounmu

Author contributions: study organisation, data collection, manuscript revision

#### 6. M.L.Samson

Author contributions: study and questionnaire design, manuscript revision

## 7. F. Wuraola

Author contributions: study design, questionnaire design, manuscript revision

#### 8. O. Olasehinde

Author contributions: study design, data collection, manuscript revision

## 9. T.P. Kingham

Author contributions: Initial conception, study design, overall supervision, manuscript revision

10. **M. Du** 

Author contributions: Initial conception, study and questionnaire design, overall supervision, manuscript revision

## Competing Interests: None to declare

**Funding:** This research was conducted with the support of the African Research Group for Oncology (ARGO) consortium. The consortium was initiated using a pilot grant funding from the National Cancer Institute's (NCI) Center for Global Health to perform dedicated cancer research in the region. This research was supported by the National Cancer Institute grant numbers R01 CA246620 and P30 CA008748.

Data sharing: No additional data available

# REFERENCES

- Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and noncommunicable diseases in low-income and middle-income countries under the Sustainable Development agenda. *Lancet* 2018;391(10134):2036-46. doi: 10.1016/s0140-6736(18)30482-3 [published Online First: 2018/04/09]
- Ezzati M, Pearson-Stuttard J, Bennett JE, et al. Acting on non-communicable diseases in low- and middle-income tropical countries. *Nature* 2018;559(7715):507-16. doi: 10.1038/s41586-018-0306-9 [published Online First: 2018/07/27]
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 2018;392(10152):1072-88. doi: 10.1016/s0140-6736(18)31992-5 [published Online First: 2018/09/29]
- 4. GLOBOCAN 2018: counting the toll of cancer. *Lancet* 2018;392(10152):985. doi: 10.1016/s0140-6736(18)32252-9 [published Online First: 2018/09/29]
- 5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68(6):394-424. doi: 10.3322/caac.21492
- 6. Olaleye O, Ekrikpo U. Epidemiology of Cancers in Sub-Saharan Africa. In: Adedeji OA, ed. Cancer in Sub-Saharan Africa: Current Practice and Future. Cham: Springer International Publishing 2017:3-19.
- Mostert S, Njuguna F, Olbara G, et al. Corruption in health-care systems and its effect on cancer care in Africa. *Lancet Oncol* 2015;16(8):e394-404. doi: 10.1016/s1470-2045(15)00163-1 [published Online First: 2015/08/08]
- 8. Harford JB. Barriers to overcome for effective cancer control in Africa. *Lancet Oncol* 2015;16(8):e385-93. doi: 10.1016/s1470-2045(15)00160-6 [published Online First: 2015/08/08]
- 9. Transforming our world : the 2030 Agenda for Sustainable Development: UN General Assembly; 21 October 2015 [Available from: <u>https://www.undp.org/content/undp/en/home/sustainable-development-goals.html</u> accessed 23 August 2019.
- Douthit NT, Alemu HK. Social determinants of health: poverty, national infrastructure and investment. BMJ Case Reports 2016;2016:bcr2016215670. doi: 10.1136/bcr-2016-
- 11. Attia-Konan AR, Oga ASS, Touré A, et al. Distribution of out of pocket health expenditures in a sub-Saharan Africa country: evidence from the national survey of household standard of living, Côte d'Ivoire. *BMC Res Notes* 2019;12(1):25. doi: 10.1186/s13104-019-4048-z [published Online First: 2019/01/17]
- Leive A, Xu K. Coping with out-of-pocket health payments: empirical evidence from 15 African countries. Bull World Health Organ 2008;86(11):849-56. doi: 10.2471/blt.07.049403 [published Online First: 2008/11/26]
- Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicountry analysis. *Lancet* 2003;362(9378):111-7. doi: 10.1016/s0140-6736(03)13861-5 [published Online First: 2003/07/18]

2	
3	
4	
5	
6	
6 7 8 9	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
20	
20 21 22 23 24 25 26 27 28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 43	
44 45	
45 46	
40 47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

- 14. Onoka CA, Onwujekwe OE, Uzochukwu BS, et al. Promoting universal financial protection: constraints and enabling factors in scaling-up coverage with social health insurance in Nigeria. *Health Res Policy Syst* 2013;11:20. doi: 10.1186/1478-4505-11-20 [published Online First: 2013/06/15]
- 15. Uzochukwu BS, Ughasoro MD, Etiaba E, et al. Health care financing in Nigeria: Implications for achieving universal health coverage. *Niger J Clin Pract* 2015;18(4):437-44. doi: 10.4103/1119-3077.154196 [published Online First: 2015/05/15]
- Aregbeshola BS, Khan SM. Out-of-Pocket Payments, Catastrophic Health Expenditure and Poverty Among Households in Nigeria 2010. *Int J Health Policy Manag* 2018;7(9):798-806. doi: 10.15171/ijhpm.2018.19 [published Online First: 2018/10/15]
- Jedy-Agba E, Curado MP, Ogunbiyi O, et al. Cancer incidence in Nigeria: a report from population-based cancer registries. *Cancer Epidemiol* 2012;36(5):e271-8. doi: 10.1016/j.canep.2012.04.007 [published Online First: 2012/05/25]
- Awodele O, Adeyomoye AA, Awodele DF, et al. Cancer distribution pattern in southwestern Nigeria. *Tanzan J Health Res* 2011;13(2):125-31. doi: 10.4314/thrb.v13i2.55226 [published Online First: 2011/04/01]
- 19. Ishola F, Omole O. A vision for improved cancer screening in Nigeria. *Lancet Glob Health* 2016;4(6):e359-60. doi: 10.1016/s2214-109x(16)30062-6 [published Online First: 2016/05/21]
- 20. Nigeria National Cancer Control Plan 2018 2022. Abuja: Federal Ministry of Health, Nigeria 2018.
- 21. World Bank staff estimates based on the United Nations Population Division's World Urbanization Prospects: 2018 Revision: The World Bank Group; [Available from: <u>https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS</u> accessed November 2019.
- 22. Kingham TP, Alatise OI. Establishing Translational and Clinical Cancer Research Collaborations Between High- and Low-Income Countries. *Annals of Surgical Oncology* 2015;22(3):741-46. doi: 10.1245/s10434-014-4342-x
- 23. Irabor DO. Emergence of Colorectal Cancer in West Africa: Accepting the Inevitable. Niger Med J 2017;58(3):87-91. doi: 10.4103/0300-1652.234076 [published Online First: 2017/05/01]
- 24. National Population Commission (NPC) [Nigeria] and ICF International. 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria, and Rockville, Maryland, USA: NPC and ICF International. <u>https://dhsprogram.com/pubs/pdf/fr293/fr293.pdf</u> (Accessed February 14, 2018).
- 25. National Bureau of Statistics (NBS) Federal Government of Nigeria. Nigeria General Household Survey, Panel 2015-2016, Wave 3. <u>http://microdata.worldbank.org/index.php/catalog/2734/study-description</u> (Accessed February 15, 2018).
- 26. Cleland CL, Hunter RF, Kee F, et al. Validity of the global physical activity questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity and sedentary behaviour. *BMC Public Health* 2014;14:1255. doi: 10.1186/1471-2458-14-1255 [published Online First: 2014/12/11]
- 27. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. *J Womens Health* 1997;6(1):49-62.
- 28. Hu FB, Satija A, Rimm EB, et al. Diet Assessment Methods in the Nurses' Health Studies and Contribution to Evidence-Based Nutritional Policies and Guidelines. *American*

*journal of public health* 2016;106(9):1567-72. doi: 10.2105/AJPH.2016.303348 [published Online First: 2016/07/28]

- 29. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and Validity of a Semiquantitative Food Frequency Questionnaire. *American Journal of Epidemiology* 1985;122(1):51-65. doi: 10.1093/oxfordjournals.aje.a114086
- Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and Validity of a Self-Administered Physical Activity Questionnaire. *International Journal of Epidemiology* 1994;23(5):991-99. doi: 10.1093/ije/23.5.991
- 31. Nigeria Demographic and Health Survey. Abuja, Nigeria: National Population Commission, Federal Republic of Nigeria, June 2014.
- 32. "Nigeria Country Briefing", Multidimensional Poverty Index Data Bank: Oxford Poverty and Human Development Initiative, University of Oxford.; 2017 [Available from: <u>www.ophi.org.uk/multidimensional-poverty-index/mpi-country-briefings/</u>. accessed August 2019 2019.
- Morhason-Bello IO, Odedina F, Rebbeck TR, et al. Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. *Lancet Oncol* 2013;14(4):e142-51. doi: 10.1016/s1470-2045(12)70482-5 [published Online First: 2013/04/09]
- Adeloye D, Basquill C, Aderemi AV, et al. An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. *J Hypertens* 2015;33(2):230-42. doi: 10.1097/hjh.00000000000413 [published Online First: 2014/11/08]
- 35. Idris IO, Oguntade AS, Mensah EA, et al. Prevalence of non-communicable diseases and its risk factors among Ijegun-Isheri Osun residents in Lagos State, Nigeria: a community based cross-sectional study. *BMC Public Health* 2020;20(1):1258. doi: 10.1186/s12889-020-09349-2
- 36. Nigeria collaborates with WHO to curb hypertension, introduces control initiative Abeokuta, Nigeria: World Health Organisation; December 2020 [Available from: <u>https://www.afro.who.int/news/nigeria-collaborates-who-curb-hypertensionintroduces-control-</u> <u>initiative#:~:text=The%20review%20estimated%20that%20prevalence,29.5%25%2C</u>

<u>%20women%2031.1%25</u>). accessed 15 April 2021 2021.

- Olasehinde O, Alatise OI, Arowolo OA, et al. Barriers to mammography screening in Nigeria: A survey of two communities with different access to screening facilities. *Eur J Cancer Care (Engl)* 2019;28(2):e12986. doi: 10.1111/ecc.12986 [published Online First: 2019/01/08]
- 38. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness in the sub-Saharan African ABC-DO cohort: African Breast Cancer—Disparities in Outcomes study. Cancer Causes & Control 2018;29(8):721-30. doi: 10.1007/s10552-018-1047-7
- 39. Makau-Barasa LK, Greene SB, Othieno-Abinya NA, et al. Improving Access to Cancer Testing and Treatment in Kenya. *Journal of Global Oncology* 2018(4):1-8. doi: 10.1200/jgo.2017.010124
- 40. Ugwumba FO, Ekwueme OE, Okoh AD. Testicular Cancer and Testicular Self-Examination; Knowledge, Attitudes and Practice in Final Year Medical Students in Nigeria. *Asian Pac J Cancer Prev* 2016;17(11):4999-5003. doi: 10.22034/apjcp.2016.17.11.4999
   [published Online First: 2016/12/30]
- 41. Mbamara SU, Ikpeze OC, Okonkwo JE, et al. Knowledge, attitude and practice of cervical cancer screening among women attending gynecology clinics in a tertiary level

1 2 3

4

5

6 7

8

9

10

11

12 13

14

15

16

17 18

19

20

21

22

medical care center in southeastern Nigeria. *J Reprod Med* 2011;56(11-12):491-6. [published Online First: 2011/12/27]

- 42. Wright KO, Kuyinu YA, Faduyile FA. Community education on cervical cancer amongst market women in an urban area of Lagos, Nigeria. *Asian Pac J Cancer Prev* 2010;11(1):137-40. [published Online First: 2010/07/03]
- 43. Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. *J Cancer Educ* 2010;25(1):106-8. doi: 10.1007/s13187-009-0023-z [published Online First: 2010/01/19]
- 44. Ajape AA, Babata A, Abiola OO. Knowledge of prostate cancer screening among native African urban population in Nigeria. *Nig Q J Hosp Med* 2010;20(2):94-6. [published Online First: 2011/01/20]
- 45. Obiechina NJ, Mbamara SU. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Niger J Med* 2009;18(4):384-7. [published Online First: 2010/02/03]
- 46. Kontis V, Mathers CD, Bonita R, et al. Regional contributions of six preventable risk factors to achieving the 25 x 25 non-communicable disease mortality reduction target: a modelling study. *Lancet Glob Health* 2015;3(12):e746-57. doi: 10.1016/s2214-109x(15)00179-5 [published Online First: 2015/10/27]
- Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: a multilevel analysis of a Nationwide survey. *BMC Womens Health* 2017;17(1):109. doi: 10.1186/s12905-017-0469-9 [published Online First: 2017/11/17]
- Masalu N, Serra P, Amadori D, et al. Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania. *International Journal of Public Health* 2017;62(7):755-62. doi: 10.1007/s00038-017-0971-8
- Kangmennaang J, Mkandawire P, Luginaah I. Breast cancer screening among women in Namibia: explaining the effect of health insurance coverage and access to information on screening behaviours. *Glob Health Promot* 2017:1757975917727017. doi: 10.1177/1757975917727017 [published Online First: 2017/09/26]
- 50. Stulac S, Binagwaho A, Tapela NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. *Lancet Oncol* 2015;16(8):e405-13. doi: 10.1016/s1470-2045(15)00161-8 [published Online First: 2015/08/08]
- 51. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. *Cancer* 2008;113(8 Suppl):2221-43. doi: 10.1002/cncr.23844 [published Online First: 2008/09/26]
- Knapp GC, Alatise OI, Olasehinde OO, et al. Is Colorectal Cancer Screening Appropriate in Nigeria? J Glob Oncol 2019;5:1-10. doi: 10.1200/jgo.19.00035 [published Online First: 2019/06/07]
- 53. Alatise OI, Ayandipo OO, Adeyeye A, et al. A symptom-based model to predict colorectal cancer in low-resource countries: Results from a prospective study of patients at high risk for colorectal cancer. *Cancer* 2018;124(13):2766-73. doi: 10.1002/cncr.31399 [published Online First: 2018/04/13]
- 54. Knapp GC, Sharma A, Olopade B, et al. An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria. *World J Surg*

2019;43(11):2674-80. doi: 10.1007/s00268-019-05100-0 [published Online First: 2019/08/14]

- 55. Olugbenga-Bello A, Adebimpe W. Knowledge and attitude of civil servants in Osun state, Southwestern Nigeria towards the national health insurance. *Nigerian Journal of Clinical Practice* 2010;13(4):421-26.
- 56. Dieleman JL, Sadat N, Chang AY, et al. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40. The Lancet 2018;391(10132):1783-98. doi: <u>https://doi.org/10.1016/S0140-6736(18)30697-4</u>
- 57. Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. *The Lancet* 2017;389(10083):1981-2004. doi: <u>https://doi.org/10.1016/S0140-6736(17)30874-7</u>
- 58. Alatise OI, Fischer SE, Ayandipo OO, et al. Health-Seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria. *Journal of global oncology* 2017;3(6):749-56. doi: 10.1200/JGO.2016.006601 [published Online First: 2017/02/01]
- 59. Yang Q, Van Stee SK. The Comparative Effectiveness of Mobile Phone Interventions in Improving Health Outcomes: Meta-Analytic Review. *JMIR Mhealth Uhealth* 2019;7(4):e11244. doi: 10.2196/11244 [published Online First: 2019/04/04]
- 60. Erwin E, Aronson KJ, Day A, et al. SMS behaviour change communication and eVoucher interventions to increase uptake of cervical cancer screening in the Kilimanjaro and Arusha regions of Tanzania: a randomised, double-blind, controlled trial of effectiveness. *BMJ Innovations* 2019:bmjinnov-2018-000276. doi: 10.1136/bmjinnov-2018-000276
- 61. Hurst TE, Semrau K, Patna M, et al. Demand-side interventions for maternal care: evidence of more use, not better outcomes. *BMC Pregnancy Childbirth* 2015;15:297. doi: 10.1186/s12884-015-0727-5 [published Online First: 2015/11/17]

Participant ID: Recruitment site: _ Interviewer ID: Patient Surname: _ All INFORMATION PLEASE NOTE IN CO PLEASE ENTER ALL PLEASE ENTER ALL Demographic Histo 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: ` 4. Has your weight c 5. Which diagram be $\widehat{\begin{subarray}{c} & & & & & & & & \\ \hline & & & & & & & & & &$	IS STRICT OVER SHE WRITTEN NUMBER ory of birth (D When did When you hanged (+/ est depicts	LY CONFIDE EET REASON N TEXT USIN RS AS VALUE DAY/MONTH, d you last fee were well) v /- 5 kg) in the	Hospital No TIAL AND FOR NON- G ONLY CA S ONLY WI (YEAR)? I well (i.e., n vhat is/was	Date qu umber D IS TO BE RESPONS PITAL LET ITH NO SY / mostly unat your weigh rs? No	Patien VSED FO E TO ANY TERS. MBOLS C / ffected by at? (Measu	MA nire admi at First N R RESEA QUESTI DR PUNC pain/disc ure to nec ncreased Age Age Age	ame: RCH PURPO ONS. TUATION. comfort)? arest kg)	SES ONLY.	E ONE) s ago) (kg) sed 5 kg	
Recruitment site: _ Interviewer ID: Patient Surname: _ All INFORMATION PLEASE NOTE IN CO PLEASE ENTER ALL <b>Demographic Histo</b> 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: ` 4. Has your weight co 5. Which diagram be $\widehat{V}$ $\widehat{V}$ $\widehat{V}$ $\widehat{V}$ $\widehat{V}$ 1 2 3 $\widehat{V}$ $\widehat{V}$ $\widehat{V}$ $\widehat{V}$ $\widehat{V}$	IS STRICT OVER SHE WRITTEN NUMBER ory of birth (D When did When you hanged (+/ est depicts	DAY/MONTH, d you last fee were well) v /- 5 kg) in the	Hospital No INTIAL AND FOR NON- G ONLY CA S ONLY WI (YEAR)? I well (i.e., n vhat is/was a past 2 year at each age	Date qu umber D IS TO BE RESPONS PITAL LET ITH NO SY / mostly unat your weigh rs? No	Patien VSED FO E TO ANY TERS. MBOLS C / ffected by at? (Measu	MA nire admi at First N R RESEA QUESTI DR PUNC pain/disc ure to nec ncreased Age Age Age	LE / FEMA inistered: ame: RCH PURPO ONS. TUATION. Comfort)? arest kg) 5 kg 10 years 20 years 30 years (if icable)	SES ONLY.	E ONE) s ago) (kg) sed 5 kg	
Interviewer ID: Phone Number Patient Surname: All INFORMATION PLEASE NOTE IN CO PLEASE ENTER ALL PLEASE ENTER ALL Demographic Histo 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: ' 4. Has your weight co 5. Which diagram be I 2 3 I 2 3	IS STRICT OVER SHE WRITTEN NUMBER ory of birth (D ) When did When you hanged (+/ est depicts	CLY CONFIDE EET REASON N TEXT USIN RS AS VALUE DAY/MONTH, d you last fee were well) v /- 5 kg) in the your <u>outline</u>	Hospital Nu FOR NON- G ONLY CA S ONLY WI (YEAR)? I well (i.e., n vhat is/was a past 2 year at each age	Date qu umber D IS TO BE RESPONS PITAL LET ITH NO SY / mostly unat your weigh rs? No	Patien Patien USED FO E TO ANY TERS. MBOLS C / ffected by nt? (Measu	Age apple	ame: RCH PURPO ONS. TUATION. Comfort)? arest kg) 5 kg 10 years 20 years 30 years (if icable)	SES ONLY.	s ago) (kg) sed 5 kg	
Phone Number Patient Surname: All INFORMATION PLEASE NOTE IN CO PLEASE ENTER ALL PLEASE ENTER ALL Demographic Histo 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: ' 4. Has your weight c 5. Which diagram be I 2 3 I 2 3	IS STRICT OVER SHE WRITTEN NUMBER ory of birth (D ) When did When you hanged (+/ est depicts	LY CONFIDE EET REASON N TEXT USIN RS AS VALUE DAY/MONTH, d you last fee were well) v /- 5 kg) in the your <u>outline</u>	Hospital No INTIAL AND FOR NON- G ONLY CA S ONLY WI (YEAR)? I well (i.e., n vhat is/was a past 2 year at each age	umber D IS TO BE RESPONS PITAL LET ITH NO SY / nostly unat your weigh rs? □ No	Patien USED FO E TO ANY TERS. MBOLS C / ffected by at? (Measu	Age apple	ame: RCH PURPO ONS. TUATION. Comfort)? arest kg) 5 kg 10 years 20 years 30 years (if icable)	SES ONLY.	s ago) (kg) sed 5 kg	
Patient Surname: _ All INFORMATION PLEASE NOTE IN CO PLEASE ENTER ALL PLEASE ENTER ALL Demographic Histo 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: 1 4. Has your weight co 5. Which diagram be 1 2 3 1 2 3 1 2 3	IS STRICT OVER SHE WRITTEN NUMBER ory of birth (D When did When you hanged (+/ est depicts	LY CONFIDE EET REASON N TEXT USIN RS AS VALUE DAY/MONTH, d you last fee were well) v /- 5 kg) in the your <u>outline</u>	I well (i.e., n what is/was at each age	D IS TO BE RESPONS PITAL LET ITH NO SY / nostly unat your weigh	Patien USED FO E TO ANY TERS. MBOLS C / ffected by ht? (Measu	Age apple	ame: RCH PURPO ONS. TUATION. Comfort)? arest kg) 5 kg 10 years 20 years 30 years (if icable)	SES ONLY.	s ago) (kg) sed 5 kg	
PLEASE NOTE IN CO PLEASE ENTER ALL PLEASE ENTER ALL Demographic Histo 1. What is your date 2. (FOR CASES ONLY) 3. (FOR CASES ADD: ' 4. Has your weight co 5. Which diagram be in the second sec	OVER SHE WRITTEN NUMBER ory of birth (D ) When did When you hanged (+/ est depicts	ET REASON N TEXT USIN RS AS VALUE DAY/MONTH, d you last fee were well) v /- 5 kg) in the your <u>outline</u>	FOR NON- G ONLY CA S ONLY WI (YEAR)? I well (i.e., n vhat is/was a past 2 year at each age	RESPONS NPITAL LET ITH NO SY / nostly unat your weigh rs? 🗌 No	E TO ANY TERS. MBOLS C / ffected by nt? (Measu	Age Age Age	ONS. TUATION. comfort)? arest kg) 5 kg 10 years 20 years 30 years (if icable)	(month	s ago) (kg) sed 5 kg	
<ol> <li>What is your date</li> <li>(FOR CASES ONLY)</li> <li>(FOR CASES ADD: 1</li> <li>Has your weight d</li> <li>Which diagram be</li> <li>Which diagram be</li> <li>1 2 3</li> <li>1 2 3</li> </ol>	of birth (D ) When did When you hanged (+/ est depicts	d you last fee were well) v /- 5 kg) in the your <u>outline</u>	I well (i.e., n what is/was past 2 year at each age	nostly unat your weigh rs? 🗌 No	ffected by nt? ( <i>Measu</i>	pain/disc ure to nec ncreased Age Age Age Age	arest kg) 5 kg 10 years 20 years 30 years (if icable)	Decrea	(kg) sed 5 kg	
<ul> <li>2. (FOR CASES ONLY)</li> <li>3. (FOR CASES ADD:</li> <li>4. Has your weight c</li> <li>5. Which diagram be</li> <li>1</li> <li>2</li> <li>3</li> <li>4. Has your weight c</li> <li>5. Which diagram be</li> </ul>	) When did When you hanged (+/ est depicts	d you last fee were well) v /- 5 kg) in the your <u>outline</u>	I well (i.e., n what is/was past 2 year at each age	nostly unat your weigh rs? 🗌 No	ffected by nt? ( <i>Measu</i>	pain/disc ure to nec ncreased Age Age Age Age	arest kg) 5 kg 10 years 20 years 30 years (if icable)	Decrea	(kg) sed 5 kg	
<ul> <li><b>3.</b> (FOR CASES ADD:</li> <li><b>4.</b> Has your weight distribution</li> <li><b>5.</b> Which diagram be</li> <li>1</li> <li>2</li> <li>3</li> <li>3</li> <li>4</li> <li>4</li> <li>4</li> <li>5</li> <li>5</li> <li>4</li> <li>4</li> <li>5</li> <li>5</li> <li>5</li> <li>6</li> <li>7</li> &lt;</ul>	When you hanged (+/ est depicts	vere well) v /- 5 kg) in the your <u>outline</u>	vhat is/was e past 2 year at each age	your weigh rs? 🗌 No	nt? ( <i>Measu</i>	Age Age Age Age Age	arest kg) 5 kg 10 years 20 years 30 years (if icable)	Decrea	(kg) sed 5 kg	
4. Has your weight d 5. Which diagram be 1 2 3	hanged (+/	/- 5 kg) in the your <u>outline</u>	at each age	rs? 🗌 No		Age	5 kg 10 years 20 years 30 years ( <i>if</i> <i>icable</i> )	Decrea	sed 5 kg	
5. Which diagram be	est depicts	your <u>outline</u>	at each age			Age Age Age Age	10 years 20 years 30 years ( <i>if</i> <i>icable</i> )	Indicate		
	Â				2	Age appla	20 years 30 years (if licable)		diagram	
					2	Age appla	20 years 30 years (if licable)		diagram	
					2	Age appla	20 years 30 years (if licable)	(1 to 9)		
					2	Age appla	20 years 30 years (if licable)			
			U U 7 8 R R			Age appla	30 years (if icable)			
		5 6	7 8 R R	9 9		appl Age	icable)			
	BE	S.A.	RA	A			40 years (if			
ŶŶŶ	ĎĒ	h th	R A	EL		annl	, ,			
M. W.	RAK		MAA	120			icable)			
JU JU JU	111 011	3636	The	1ET			50 years (if licable)			
20 20 20	18( )		11/ 11-1			Curr				
	00 0	1 20	या या	23						
6. What is your heigh				_	cm)					
7. What is your curre				_ Widowe		Married	Divo			ſ
8. Has anyone in you				•	illdren) col	mpleted s	secondary sci	hool or abo	ve? 🔄 Yes	l
<b>9.</b> What is the highes				_		. —	—			
No formal education				_		al 门 Ur	niversity [_] (	Graduate so	chool	
<b>10.</b> What is/was you			-	-		Data	Calf	Detta	Church	
Uner	nployed	Pensioner	Civil Servant	Trader	Farmer	Driver	Self Employed	Retired	Student	Oth
Current										
Less than 2										
years ago			_					ļ	ļ	
More than										
2 years ago										

BMJ Open

Page 2 of 12

	LGA/Distr	ict	Landmark	Villag	e Name
13. What tribe do you bel	ong to? 🗌 Yoruba	🗌 Ibo	🗌 Hausa	Other	(specify)
14. Including yourself, how	w many people live	in your household?	)		
15. Including you, what w	as your <u>household'</u>	<u>s</u> AVERAGE MONTH	ILY combined income	(including all sourc	es) over the last year?
		: know AVERAGE MONTHI			21000 Naira?  Yes  No 34000 Naira?  Yes  No
<b>16.</b> What was your <u>persor</u>	nal AVERAGE MONT	HLY income (incluc	ling all sources) over	the last year?	
(Naira)	$\sqrt{1}$ If refused/don't	: know	ncome last year less t	han 21000 Naira?	☐ Yes ☐ No
			ncome last year less t		Yes No
<b>17.</b> What type of toilet do			(flushable) 🗌 Pit la 	trine with vent pipe	e 🗌 Unventilated pit latrine
18. Is your toilet shared w	vith another househ	old? 🗌 Yes 🛛	No		
<b>19.</b> What is the source of River/spring	your water supply?		] Public tap 🛛 🗍 B ] Other	orehole or pump	Dug well
20. Is your source of wate Yes No ↓ If no 20a. Is your wate			by foot (to and from)	? 🗌 Yes 📃 No	
<b>21.</b> Does the construction	of your source of w	vater protect the w	ater from outside co	ntamination? 🗌 Ye	es 🗌 No 📄 Don't Know
<b>22.</b> What type of floor do	· ·	ome? Dirt/clay/earth	Sand	Dung	Other
<b>23.</b> Which of these do you Electricity (Connected Air conditioner		power gr <u>id)</u>		=	frigerator 🔲 Telephone ole (DSTV, etc.)
<b>24.</b> What is your <u>primary</u> Charcoal or coal			] Electric cooker ] Other	Gas cooker	Kerosene stove
<b>25.</b> Do you own any of the Personal car or truck		as many as may ap Motorcycle		omobiles	
<ul> <li>26. Do you have National</li> <li>Yes No (go to que</li> <li>↓ If yes</li> <li>26a. When did you last us</li> </ul>	stion 27)		s More than	2 years ago	
<b>26b.</b> Including yourself, he					
<b>27.</b> If no insurance, what a Too Expensive Unaware of the NHIS	Doesn't cover		nce? (Select as many costs 🗌 Too difficu		
<b>28.</b> Did you have any majo ☐Yes ☐No ↓ If yes	or medical costs in t	he last 2 years (reg	ardless of insurance	status)?	
<b>28a.</b> Please specify what f	or		and estimated cost _	(Na	iira)
	For peer review o	only - http://bmjop	en.bmj.com/site/abc	out/guidelines.xhtn	h

					(If <u>newly</u> di	ear of diagnos agnosed mult oct all that app	iple times,	Curr be trea	ing
	Yes		No	If Yes →	More than 10 years ago	5 to 10 years ago	Less than 5 years ago	Yes	N
Tuberculosis (TB)						10010 080	70010 0.80		
Malaria			Π					П	
HIV			Π						
Hepatitis B (HBV)			Π						
Hepatitis C (HCV)	$\Box$		$\overline{\Box}$						
Amoebic infection									
Schistosomiasis									
Giardia									
Other parasitic infection (specify)									
Chronic Obstructive Pulmonary Disease (COPD)			Π						
Sickle Cell Disease (SCD)			Π						
Peptic Ulcer Disease	Ē								
Diabetes									
Hypertension (high blood pressure)					0				
Myocardial infarction (heart attack)									
High cholesterol									
Stroke or mini-stroke	H		Ħ						
Asthma	H		Ħ					H	
Epilepsy	H		Ħ					H	
Cancer	Ē		Π						
(specify)									
<ul> <li><b>10</b>. (FOR CASES ADD: Prior to Less than 1 year ago</li> <li><b>11</b>. Have you ever seen a trad</li> <li><b>15</b>. Yes</li> <li><b>16</b> No (go to Vietaling)</li> <li><b>17</b> Saw &lt;2 YEARS AGO</li> <li><b>18</b> Saw 2+ YEARS AGO</li> </ul>	1-4 y	ears I he	s ago aler	9 5-10 ?	r diagnosis) whe ) years ago [		t time you rece 10 years ago	ived ca	re in
<b>1a.</b> Did you receive any treat	ment	?		Yes		(specify)	🗌 No		
<b>2.</b> Do you use traditional ren	nedies	at	hom	e?					
Yes(s	necify	/)		No (go t	to question 33)				
Used <2 YEARS AGO	peen	,,							

33. Have you ever had colorectal cancer screening? 🗌 Yes 🗌 No (go to question 34) 🗌 Never	heard of this (go to question
(e.g., Colonoscopy/sigmoidoscopy, stool test) $\forall$ If yes (Select all that apply.)	100 10 400 100 100 100 4000100
*Colonoscopy/sigmoidoscopy: internal view of	GO
intestines/colon via inserted camera* Colonoscopy/sigmoidoscopy 10+ YEARS A	
Stool test <2 YEARS AGO	
Stool test 2+ YEARS AGO	
$\checkmark$	
<b>33a</b> . Did you receive any treatment?	_
Yes(specify)	No
34. (FOR WOMEN ONLY)	
Have you ever had cervical cancer screening? Yes No (go to question 35) Never	heard of this (go to question
(e.g. Pap smear, HPV testing) ↓ If yes *collecting cells from cervix to test for cancer* ☐ cervical cancer screening <3 YEARS AGO	
*collecting cells from cervix to test for cancer *	
<b>34a.</b> Did you receive any treatment?	
	No
	<b>_</b> -
35. (FOR WOMEN ONLY)	
Have you ever had breast cancer screening? 📉 🔲 Yes 🔲 No (go to question 36) 🗌 Never	heard of this (go to question
(e.g. Mammogram)	
*x-ray of breasts*	
Mammogram 2+ YEARS AGO	
$\checkmark$	
<b>35a</b> .Did you receive any treatment?	_
Yes(specify)	No
Tamilu Uistam	
Family History	
<b>36.</b> Have any of these relatives had the following cancers? (Select as many as may apply.)	
No family history of cancer (go to question 37)	
Mother Father Brother Sister	
Lung	
Dreast View View View View View View View View	
Breast     Image: Color or rectal       Prostate     Image: Color of the second secon	
Prostate	
Cervical	
Uterine (endometrial)	
Ovarian	
Pancreas	
Other/unknown(specify)	

Page 37 of 45

Yes, smoked	noked 5 packs of in past, but quit	-	Ye	s, current	y smoke		No (	go to que	stion 39
If smoked in			ltc	urrently s	noke				
Quit <2 YEAF									
Quit 2+ TEAF 1.	NS AGO		Ļ						
¥ 38a Ateacha	ge: Average nun	ober of ci	v varettes	ner dav					
	ge. Average nun		None		5-14	15-24	25-35	36-44	45+
Current			Vone	14	514	15 24	25 55	30 44	431
<2 years ago									
Age < 15 years									
Age 15-19 year									
	rs (if applicable)								
	rs (if applicable)		•						
	rs ( <i>if applicable</i> )								
	rs ( <i>if applicable</i> )								
Age 60 to the p	present ( <i>if applic</i>	able)							
☐ Yes, drank ir ↓ If drank in pa ☐ Quit <2 YEAF	RS AGO	glass of v	🗌 Ye	urrently dr	y drink a	lcohol	No (į	go to que	stion 41
<ul> <li>Yes, drank ir</li> <li>↓ If drank in pa</li> <li>Quit &lt;2 YEAF</li> <li>Quit 2+ YEAF</li> <li>↓</li> <li>40a. At each ti</li> </ul>	n past, but quit st RS AGO	al numbe	☐ Ye If cu	es, current urrently dr	y drink a ink		ttles/cans	s of • per	stion 41
<ul> <li>Yes, drank ir</li> <li>↓ If drank in pa</li> <li>Quit &lt;2 YEAF</li> <li>Quit 2+ YEAF</li> <li>↓</li> <li>40a. At each ti</li> <li>beer, glasses of</li> </ul>	n past, but quit st RS AGO RS AGO <b>me period: Usua</b> of wine, shots of None or less	al numbe liquor)	☐ Ye If cu V r of drin	ks (e.g., to 2-4 per	y drink a ink otal numb	per of bot	itles/cans	s of • per	stion 41
Yes, drank ir ↓ If drank in pa Quit <2 YEAF Quit 2+ YEAF ↓ 40a. At each ti beer, glasses o	n past, but quit st RS AGO Me period: Usua of wine, shots of None or less than 1	al numbe liquor) 1-3 per	☐ Ye If cu V r of drin	ks (e.g., to 2-4 per	y drink a ink otal numk 5-6 per	per of bot	itles/cans	s of • per	stion 41
Yes, drank ir ↓ If drank in pa Quit <2 YEAF Quit 2+ YEAF ↓ 40a. At each ti beer, glasses o Current <2 years ago	n past, but quit st RS AGO Me period: Usua of wine, shots of None or less than 1	al numbe liquor) 1-3 per	☐ Ye If cu V r of drin	ks (e.g., to 2-4 per	y drink a ink otal numk 5-6 per	per of bot	itles/cans	s of • per	stion 41
Yes, drank ir ↓ If drank in pa Quit <2 YEAF Quit 2+ YEAF ↓ 40a. At each ti beer, glasses o	n past, but quit st RS AGO Me period: Usua of wine, shots of None or less than 1	al numbe liquor) 1-3 per	☐ Ye If cu V r of drin	ks (e.g., to 2-4 per	y drink a ink otal numk 5-6 per	per of bot	itles/cans	s of • per	stion 41

BMJ Open

Page 6 of 12

	of the following m	hedicat	ions?				Fragues	ncy * <i>in th</i>	a last 2 y	oarc*	
						(*/				vere well)	1
	Ever taken	IF yes →	Taken in past 2 ye		1 da mon or le	iy a hth	2-3 days a month	One day a week	2-3 days a week	4-5 days a week	6+ day wee
Acetaminophen (e.g., Panadol, Paracetamol,	Yes No		Yes [				month	WEEK	WEEK	WEEK	wee
Tylenol) Aspirin (e.g., Anacin, Buffurin Allus Calenar)	Yes 🗌 No		Yes [	] No	-						
Bufferin, Alka-Seltzer) Other anti-				-							
inflammatory (e.g., Ibuprofen, Diclofenac, Indocin, Naprosyn, Advil)	🗌 Yes 🗌 No		Yes [	] No							
Anti-high blood pressure	Yes No		Yes [	] No							
Anti-diabetic (e.g., Metformin)	Yes No		Yes [	] No							
Anti-high cholesterol	Yes No		Yes	No							
Multivitamin	Yes No		Yes	No							
Folate only/vitamin B9 supplement	🗌 Yes 🗌 No		Yes [	] No							
Calcium only supplement	🗌 Yes 🗌 No		Yes [	] No							
Vitamin D only supplement	Yes No		Yes [		•						
Steroid	Yes No		Yes _	No							
Herbal supplements	🗌 Yes 🗌 No		Yes 🗌	No							
Yes No (go to que If yes 2a. Select as many as m Cipro tab (ciprofloxac Amoxil (amoxicillin) 2b. Have you taken any Yes, taken in past, bue If taken in past Most recently stoppe Most recently stoppe	ay apply: in)	her ant e last 2	etronidazol tibiotic <i>years</i> * (* <b>F</b> Yes, curren	(specify OR CASES	)				piclox (ar	npicillin cl	oxacil
,						-					
<b>3.</b> At each period of you	N	lone		3-15 16 days to	days 2	>2-4 months		>2-4 s year		s	
			7 days		onths		to 2 years				
			7		onths						
<b>3.</b> At each period of you			7		onths						
					onths		to 2				

## BMJ Open

Zentel (albendazole) Verme			_(specify)			trax		
<ul> <li>44b. Have you taken any antiparasitic</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> </ul>				ing No		<b>ISE</b> : when y	ou were	weii*)?
Most recently stopped 6+ WEEKS								
<b>45.</b> At each period of your life: Indicat								
	None	Less than 7 days	8-15 days	16 days to 2 months	>2-4 months	>4 months to 2 years	>2-4 years	4+ years
During the past 2 years		uayo				years		
Age < 19 years								
Age 20-39 years (if applicable)								
Age 40-59 years (if applicable)		<u> </u>	ļ					
Age 60 to the present ( <i>if applicable</i> )								
<ul> <li>46a. Select as many as may apply:</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> </ul>	quin) 🗌 (spe * <i>in the la</i> .	Pyrimeth Atovaque cify) st 2 years	amine/si one/prog * (* <b>FOR (</b>	ulfadoxine uanil (e.g.,	(e.g., Fansi Malanil, N When you	dar) [ lalarone) [	Amod Quinir	aquine (Ca
<ul> <li>46a. Select as many as may apply: </li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> </ul>	quin)	Pyrimeth Atovaque ccify) st 2 years Yes, curr	aamine/so one/prog * (* <b>FOR (</b> ently taki	ulfadoxine ( uanil (e.g., C <b>ASES USE</b> : ing No	(e.g., Fansi Malanil, N When you	dar) [ lalarone) [ were well*	Amod Quinir	aquine (Ca
<ul> <li>46a. Select as many as may apply: </li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ng No No 9 you used a 16 days	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: </li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than	aamine/so one/prog * (* <i>FOR (</i> ently taki	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, N When you D <b>any</b> antima	dar) [ lalarone) [ were well* alarial: >4 months	_ Amod _ Quinir )?	aquine (Ca
<ul> <li>46a. Select as many as may apply: </li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ng No No 9 you used a 16 days	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months to 2	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: </li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: ☐</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicate</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months to 2	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: ☐</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicat</li> <li>During the past 2 years</li> <li>Age &lt; 19 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months to 2	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: ☐</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicat</li> <li>During the past 2 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> <li>Age 40-59 years (<i>if applicable</i>)</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months to 2	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>46a. Select as many as may apply: ☐</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicat</li> <li>During the past 2 years</li> <li>Age &lt; 19 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7	amine/so one/prog * (* <i>FOR (</i> ently taki <u>nt of time</u> <b>8-15</b>	ulfadoxine ( uanil (e.g., CASES USE: ing No e you used a 16 days to 2	(e.g., Fansi Malanil, M <i>When you</i> o <b>any</b> antima <b>&gt;2-4</b>	dar) [ lalarone) [ were well* alarial: >4 months to 2	Amod Quinir )? 	aquine (Ca le <b>4</b> +
<ul> <li>☐ Chloroquine (e.g., Aralen)</li> <li>☐ Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>☐ Yes, taken in past, but stopped</li> <li>↓ If taken in past</li> <li>☐ Most recently stopped &lt;6 WEEKS</li> <li>☐ Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicat</li> <li>☐ During the past 2 years</li> <li>Age &lt;19 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> <li>Age 60 to the present (<i>if applicable</i>)</li> </ul>	quin)	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7 days	amine/su one/prog * (* <i>FOR (</i> ently taking t of time <b>8-15</b> days	Lufadoxine ( Luanil (e.g., CASES USE: ing No e you used a 16 days to 2 months	(e.g., Fansi Malanil, N When you o any antima >2-4 months	dar) [ lalarone) [ were well* alarial: >4 months to 2 years	Amod Quinir )? >2-4 years	4+ years
<ul> <li>46a. Select as many as may apply: ☐</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicat</li> <li>During the past 2 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> <li>Age 40-59 years (<i>if applicable</i>)</li> </ul>	quin) (spe * in the la. AGO AGO AGO AGO AGO AGO AGO AGO	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7 days	amine/so one/prog * (*FOR ( ently taking t of time 8-15 days	ulfadoxine (         uanil (e.g.,         CASES USE:         ing       No         e you used a         16 days         to 2         months	(e.g., Fansi Malanil, M When you o any antima >2-4 months	dar) [ lalarone) [ were well* alarial: >4 months to 2 years	Amod Quinir )? >2-4 years	4+ years
<ul> <li>46a. Select as many as may apply: □</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicate</li> <li>During the past 2 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> <li>Age 40-59 years (<i>if applicable</i>)</li> <li>Age 60 to the present (<i>if applicable</i>)</li> <li>Age (years) your menstrual periods</li> <li>Have your menstrual periods stop</li> <li>Yes</li> <li>No</li> </ul>	quin) (spe * in the la. AGO AGO AGO AGO AGO AGO AGO AGO	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7 days 0N IS FO anently?	amine/so one/prog * (* <i>FOR (</i> ently taking t of time <b>8-15</b> days days R WOME _ (years) <sup>*</sup>	ulfadoxine (         uanil (e.g.,         CASES USE:         ing       No         e you used a         16 days         to 2         months	(e.g., Fansi Malanil, N When you o any antima >2-4 months PANTS ONI fused/Don	dar) [ lalarone) [ were well* alarial: >4 months to 2 years years	Amod Quinir )? >2-4 years	4+ years
<ul> <li>46a. Select as many as may apply: □</li> <li>Artesunate/mefloquine (e.g., Arte</li> <li>Chloroquine (e.g., Aralen)</li> <li>Other antimalarial</li> <li>46b. Have you taken any antimalarial</li> <li>Yes, taken in past, but stopped</li> <li>If taken in past</li> <li>Most recently stopped &lt;6 WEEKS</li> <li>Most recently stopped 6+ WEEKS</li> <li>47. At each period of your life: Indicate</li> <li>During the past 2 years</li> <li>Age 20-39 years (<i>if applicable</i>)</li> <li>Age 40-59 years (<i>if applicable</i>)</li> <li>Age 60 to the present (<i>if applicable</i>)</li> <li>Age (years) your menstrual periods</li> <li>49. Have your menstrual periods stop</li> </ul>	quin) (spe (spe *in the la. AGO AGO AGO AGO AGO AGO AGO AGO AGO AGO	Pyrimeth Atovaque crify) st 2 years Yes, curr AL amoun Less than 7 days	amine/se one/prog * (*FOR ( ently taking 8-15 days and a solution Refused/	Alfadoxine ( uanil (e.g., CASES USE: ng No e you used a 16 days to 2 months NPARTICIE * * If Re	(e.g., Fansi Malanil, M When you o any antima >2-4 months pants ONI fused/Don	dar) [ lalarone) [ were well* alarial: >4 months to 2 years years	Amod Quinir )? >2-4 years	4+ years

					ſ	age 8 of		
50a. Age at first pregnancy _	(years)	*	*If Refused/	Don't Know, enter S	999			
50b. Age at birth of first child	d (yea	rs)*	*If Refused/	Don't Know, enter 9	999			
50c. Age at birth of last child	(year	^s)*	*If Refused/	Don't Know, enter 9	999			
<b>50d.</b> Number of live births _			*If Refused/	Don't Know, enter 9	999			
<b>50e.</b> Number of incomplete		*						
50f. Average breastfeeding of						36+		
50g. Average time between	births (years)	<1	□ 1-2 □	3-4 4-7 8-	+ years			
50h. In what way/ways was	your child/child	dren deliv	ered? (Select	all that apply.) 🗌	Vaginal birth 🔲 (	C-section		
<ul> <li>Yes, used in past, but sto</li> <li>↓ if used in past</li> <li>Stopped &lt;2 YEARS AGO</li> <li>Stopped 2+ YEARS AGO</li> <li>↓</li> <li>51a. For how long did you us</li> <li>51b. Type of hormone used</li> <li>51c. Hormone use pattern [</li> <li>52. Have you EVER used oral</li> <li>Yes, used in past, but sto</li> <li>↓</li> <li>Stopped &lt;2 YEARS AGO</li> <li>↓</li> </ul>	e these hormo most recently? Continuous contraceptive	rently use ones (year Oral 2 v s (OC's) fo	s)?	☐ 1 ☐ 2 ☐ Vaginal (contraception, acr	3-4 5. Other	7 🗌 8+ — ularity, eta	c.)?	
🗌 None 🔄 Oral contrac	eptive 🗌 S	oonge	🗌 Diaphragr	n/cervical cap	] Tubal ligation (tu	bes tied)	🗌 Foa	
None       Oral contract         Intrauterine device       Intrauterine device         Nutrition History         54. (FOR CASES ADD: When the second	eptive S Condom ( you were well) less than onc 5-6 times a w	bonge Vasector How ofte te a mont veek	Diaphragr ny Imp n did/do you n I	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more	bes tied) F f f f f f f f f f f f f f f f f f f	Foa Refused/I st year? Y	Don't Know
None Oral contrac Intrauterine device Nutrition History  A. (FOR CASES ADD: When Contract of the second se	eptive Si Condom ( you were well) less than onc 5-6 times a w you were well)	oonge Vasector How ofte e a mont veek Kindly re	Diaphragr ny Imp n did/do you n I call your food	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling	bes tied) 	Foa Refused/I st year? y tion. (Sel	oon't Know
Intrauterine device Nutrition History  G4. (FOR CASES ADD: When The second sec	eptive SI Condom SI you were well) less than ond 5-6 times a w you were well) otographic guid	bonge Vasector How ofte te a mont veek Kindly re <b>de for spe</b>	Diaphragr ny Imp n did/do you n Imp call your food cific foods ar	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling	bes tied) 	Foa Refused/I st year? y tion. (Sel	Don't Know
None       Oral contraction         Intrauterine device       Intrauterine device         Nutrition History         54. (FOR CASES ADD: When the second sec	eptive SI Condom SI you were well) less than ond 5-6 times a w you were well) otographic guid	bonge Vasector How ofte te a mont veek Kindly re <b>de for spe</b>	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling	bes tied) 	Foa Refused/I st year? y tion. (Sel	Don't Know
None       Oral contraction         Intrauterine device       Intrauterine device         Nutrition History         54. (FOR CASES ADD: When the second sec	eptive SI Condom SI you were well) less than ond 5-6 times a w you were well) otographic guid (Page 2 of pho Medium	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
None Oral contraction intrauterine device Nutrition History 54. (FOR CASES ADD: When Sever Solution of the second sec	eptive SI Condom SI vou were well) less than onc 5-6 times a w vou were well) otographic guid (Page 2 of pho Medium serving 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contract</li> <li>Intrauterine device</li> <li>Intrauterine device</li> <li>Nutrition History</li> <li>54. (FOR CASES ADD: When Your Set and the se</li></ul>	eptive Si Condom Si You were well) less than onc 5-6 times a w You were well) tographic guid (Page 2 of pho Medium serving 35cl 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contract</li> <li>Intrauterine device</li> <li>Intrauterine device</li> <li>Nutrition History</li> <li>54. (FOR CASES ADD: When Contract</li> <li>Never</li> <li>2-4 times a week</li> <li>2-4 times a week</li> <li>55. (FOR CASES ADD: When Contract</li> <li>Soft (FOR CASES ADD: When Contract</li> <li>Soft drinks e.g coca cola</li> <li>Natural fruit juice</li> <li>Juice blends e.g 5 alive</li> <li>Milk and milk products</li> </ul>	eptive SI Condom SI vou were well) less than onc 5-6 times a w vou were well) otographic guid (Page 2 of pho Medium serving 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contrac</li> <li>Intrauterine device</li> <li>Intrauterine device</li> <li>Nutrition History</li> <li>54. (FOR CASES ADD: When</li> <li>Never</li> <li>2-4 times a week</li> <li>2-4 times a week</li> <li>55. (FOR CASES ADD: When</li> <li>many as may apply.) See photogram</li> <li>Beverages and Other Drinks</li> <li>Beverages and Other Drinks</li> <li>Soft drinks e.g coca cola</li> <li>Natural fruit juice</li> <li>Juice blends e.g 5 alive</li> <li>Milk and milk products</li> <li>e.g yoghurt</li> </ul>	eptive Si Condom Si You were well) less than onc 5-6 times a w you were well) tographic guid (Page 2 of pho Medium serving 35cl 35cl 35cl 35cl ½ litre	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contract</li> <li>Intrauterine device</li> <li>Intrauterine device</li> <li>Nutrition History</li> <li>54. (FOR CASES ADD: When Contract</li> <li>Never</li> <li>2-4 times a week</li> <li>2-4 times a week</li> <li>55. (FOR CASES ADD: When Contract</li> <li>Soft (FOR CASES ADD: When Contract</li> <li>Soft drinks e.g coca cola</li> <li>Natural fruit juice</li> <li>Juice blends e.g 5 alive</li> <li>Milk and milk products</li> </ul>	eptive Si Condom Si You were well) less than onc 5-6 times a w You were well) tographic guid (Page 2 of pho Medium serving 35cl 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contrac</li> <li>Intrauterine device</li> <li>Intrauterine device</li> <li>Nutrition History</li> <li>54. (FOR CASES ADD: When of the second seco</li></ul>	eptive S Condom S Condom ( ) Condom ( ) Source well) Source well Source well) Source well Source well) Source well Source well Sourc	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
<ul> <li>None Oral contraction of the image of the image.</li> </ul>	eptive S Condom S Condom ( ) Condom ( ) Source well) Source well Source well) Source well Source w	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
None       Oral contract         Intrauterine device       Intrauterine device         Nutrition History         54. (FOR CASES ADD: When         Never       1         2-4 times a week       1         55. (FOR CASES ADD: When         many as may apply.) See pho         Beverages and Other Drinks         Soft drinks e.g coca cola         Natural fruit juice         Juice blends e.g 5 alive         Milk and milk products         e.g yoghurt         Kunu, sobo         Coffee         Tea	eptive Si Condom Si Condom Si you were well) less than onc 5-6 times a w you were well) tographic guid (Page 2 of pho Medium serving 35cl 35cl 35cl ½ litre 35cl 35cl 35cl 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times
None       Oral contract         Intrauterine device       Intrauterine device         Nutrition History         54. (FOR CASES ADD: When         Never       2-4 times a week         2-4 times a week       55. (FOR CASES ADD: When         many as may apply.) See pho         Beverages and Other Drinks         Soft drinks e.g coca cola         Natural fruit juice         Juice blends e.g 5 alive         Milk and milk products         e.g yoghurt         Kunu, sobo         Coffee         Tea         Water	eptive Si Condom Si Condom Si you were well) less than onc 5-6 times a w you were well) tographic guid (Page 2 of pho Medium serving 35cl 35cl 35cl ½ litre 35cl 35cl 35cl 35cl 35cl	oonge Vasector How ofte e a mont veek Kindly re de for spe btographi Serving	Diaphragr ny Imp n did/do you n D call your food cific foods ar c guide) g Never	n/cervical cap	Tubal ligation (tu Other aurant and/or buk 1 time a w 2 or more ast year when filling size. *S=Small, M 1 time 2-4 a times week a	bes tied) 	Foa Refused/I st year? y tion. (Sel , <b>L=Large</b> 1 time a	ect as * 2 or more times

ſ	Meats, Fish,	Chicken, a	nd Eggs	(Pages 2	1 and 3	of ph	otographic g	guide)

	Medium	Se	rving	, S	Never	Less	1-3	1	2-4	5-6	1	2 or
	serving					than	times	time	times	times	time	mor
						once a	а	а	а	а	а	tim
					1	month	month	week	week	week	day	a da
		S	Μ	L								
Fried beef/veal/pork/lamb/goat	1 cut		-									
Fried fish	1 cut											
Fried chicken	1 cut											
Fried egg Boiled beef/veal/	1 egg											
pork/lamb/goat	1 cut											
Boiled fish/chicken/egg	1 cut/											
	1 egg						-					<u> </u>
Smoked beef/veal/pork/lamb/goat	1 cut											
Smoked fish	1 cut											
Grilled/roasted beef/veal/pork/	1 cut or 3											
lamb/goat	sticks											
e.g. suya, asun, kilishi, ponmo												
Grilled/roasted fish	1 cut											
Offal	1 cut											
e.g. abodi, shaki, ifun												
Bushmeat/wildmeat	1 cut											
Snails	1 snail 📃											
Other												
Snacks (Pages 1 and 4 of photograph	ic guide)											
······································	Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 or
	serving	S	M	L		than	times	time	times	times	time	mor
		-				once a	а	а	а	a	а	time
						month	month	week	week	week	day	a da
Fried snacks e.g. puff puff, chin	½ cup										/	
chin, donut, buns, plantain chip						$\mathbf{N}_{\star}$						
Baked Snacks	1 medium											
e.g pie, biscuit, cake	package											
Roasted /popped Snacks	½ cup											
e.g. popcorn, corn	72 Cup											
Nuts	½ cup											
e.g. kola nut, gancina kola, walnut,	, - oup											
cashew nut, tiger nut												
Other												
Grains, Cereals, and Products (Pages	1 and 5 of pho	otogi	raph	ic gı	uide)							
	Medium	Se	ervin	g	Never	Less	1-3	1	2-4	5-6	1	2 or
	serving			-		than	times	time	times	times a	time	mor
	_					once a	а	а	а	week	а	time
						month	month	week	week		day	a da
				L								
		S	Μ					1	1	1		
Fermented milled cereals	1 cup or 1	S	IVI									
Fermented milled cereals e.g. pap, eko	1 cup or 1 wrap (eko)	S										
e.g. pap, eko												
e.g. pap, eko Boiled cereals	wrap (eko)											
e.g. pap, eko Boiled cereals e.g maize, rice	wrap (eko)											
e.g. pap, eko Boiled cereals e.g maize, rice Whole meal product	wrap (eko) 1 cup cooked 1 cup or 1											
e.g. pap, eko Boiled cereals e.g maize, rice Whole meal product e.g wheat, maize, rice	wrap (eko) 1 cup cooked 1 cup or 1 wrap											
e.g. pap, eko Boiled cereals e.g maize, rice Whole meal product	wrap (eko) 1 cup cooked 1 cup or 1											

BMJ Open

Page 10 of 12

Page 42 of 45

Serving       Never serving       Less than month       1-3 times       1 time a week       2-4 times       5-6 times times a a       1 times a a         30iled tubers e.g. yam, cocoyam, otatoes       1 cup or 1 wrap       S       M       L       -<		Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 or
S         M         L         Image: Conce a i		serving		-			than	times	time	times	times	time	moi
Solided beams e.g. evan riro, moin moin, groundnutI cup cooked or 1 wrapMLmonth weekmonth weekweekweekday weekday daySolided beams e.g. ewan riro, moin or, groundnut1 cup or 1 wrapIII <t< th=""><th></th><th>0</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>tim</th></t<>		0											tim
S         M         L         Image: Cooked or relation of the cooked or									-				a da
Bailed beans e.g. ewa riro, moin moin, groundnut         1 cup or 1 wrap         I cup or 1 wrap         I cup or 1 wrap         I cup or         I cup or <thi cup<br="">or         I cup or         <thi cup<br="">or</thi></thi>			S	М	1		month	month	Week	Week	Week	uuy	446
noin, groundnut         cooked or 1 wrap         Image         I	Boiled beans e.g ewa riro, moin	1 cup	-										
or 1 wrap         or 1 wrap         or         or         or         or         or           Sigy product e.g. cheese, milk         1 cup         0	-												
1 wrap         1 wrap         1 <th1< th=""> <th1< th="">         1         <th1<< td=""><td>, 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th1<<></th1<></th1<>	, 0												
Solid control of the serving gate of the se													
Soy product e.g. cheese, milk         1 cup         I <thi< th="">         I         I         &lt;</thi<>	Fried legume product e g akara												
Dther		-											
Serving       Never serving       Less than month       1-3 times       1 time a week       2-4 times       5-6 times times a a       1 times a a         30iled tubers e.g. yam, cocoyam, otatoes       1 cup or 1 wrap       S       M       L       -<	Other	1 000											
Medium serving         Serving         Never less than month         Less than time a month         1 - 3 time a month         1 time time a week         2-4 time a a a a a week         5-6 time a a a a a a a a         1 time time a a a a           30iled tubers e.g. yam, cocoyam, Dotatoes         1 cup or 1 wrap         S         M         L         -						I							
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	Roots/Tubers and Products (Page 7		ī —	-	e)	Never	Loss	1.2	1 + 1 - 2 - 2	2.4	ГС	1	2.0
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			Ser	ving		Never		-					20
SMLmonthmonthweekweekdaySolied tubers e.g. yam, cocoyam, botatoes1 cup or 1 wrapIII<		serving											mo
S         M         L         Image         Image <thimage< th=""> <thimage< th=""> <thimage< th=""></thimage<></thimage<></thimage<>									week				tim
Boiled tubers e.g. yam, cocoyam, original products       1 cup or 1 wrap       Image       Image </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>month</td> <td>month</td> <td></td> <td>week</td> <td>week</td> <td>day</td> <td>a d</td>							month	month		week	week	day	a d
botatoes         wrap         I <thi< th="">         I         <thi< th="">         I         I         <thi<< td=""><td></td><td></td><td>S</td><td>M</td><td>L</td><td></td><td></td><td> </td><td></td><td></td><td></td><td></td><td> </td></thi<<></thi<></thi<>			S	M	L								
Cassava products       1 wrap       1					1								
a.g. garri. eba, fufu       5 slices       5 slices       1	•				-								
S slices		1 wrap			1								
e.g fried yam, potatoes, cocoyam          I <thi< th="">         I         <thi< th=""></thi<></thi<>					-								
Other	•	5 slices		$\sim$									
uits/ Vegetables and Products (Pages 1, 8, and 10 of photographic guide)         Medium serving       Serving       Never       Less       1-3       1       times a month       1-4       times a month       1       5-6       1         Mole fruit       1 fruit (medium)       S       M       L       Never       Less       1-3       1       2-4       5-6       1       times a week       a week					6								
Medium servingServingServingNever servingLess than once a month1-3 times a a month12-4 times a <td>Other</td> <td></td>	Other												
Medium servingServingServingNever servingLess than 	ruits/ Vegetables and Products (Pa	ages 1, 8, and	1 10 d	of pho	otog	raphic gu	ide)						
serving     serving     than once a a month     times a a month     times a a a a month     times a a a a a a a a a a a a a a a a a a a								1-3	1	2-4	5-6	1	2 or
Multiple         Image: Control of the serving				0			than				times		mo
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		0					once a	а	а	а	а	а	tim
Whole fruit       1 fruit       1 fruit       Image: mango, banana, agbalumo, breadfruit       1 fruit       Image: mango, banana, agbalumo, breadfruit       Image: mango, banana, bana, banana, bana, banana, banana, bana, banana, banana, b							month	month	week	week	week	day	a da
e.g orange, mango, banana, agbalumo, breadfruit       (medium)       I </th <th></th> <th></th> <th>S</th> <th>М</th> <th>L</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>			S	М	L								
agbalumo, breadfruit1 cupIIIIIIIProcessed fruit1 cup1 cupIIIIIIIIFried plantain1 fruit (medium)1 fruit (medium)III	Whole fruit	1 fruit					4						
agbalumo, breadfruit1 cupIIIIIIIProcessed fruit1 cup1 cupIIIIIIIIFried plantain1 fruit (medium)1 fruit (medium)III	e.g orange, mango, banana,	(medium)											
Perocessed fruit1 cupII		, ,											
Fried plantain       1 fruit (medium)       1		1 cup						$\mathbf{O}$					
(medium)(medium		-											
Grilled/roasted plantain e.g. Boli       1 fruit (medium)       1 fruit (medi													
(medium)(medium	Grilled/roasted plantain e.g. Boli			1									
eafy vegetables       ½ plate       ½ plate       1													
e.g pumpkin, amaranth, worowo, ewuro, spinach // 2 cup //	Leafy vegetables												
ewuro, spinach // Cup /													
Dther vegetables       ½ cup       ½ cup       Image: Second Se													
e.g okra, onion, tomato, garden egg, cucumber, carrot, pepper Other in	-	1/ cup											
egg, cucumber, carrot, pepper	Other vegetables	72 cup											
Dther	e g okra onion tomato gardon	1											
Medium       Serving       Never       Less       1-3       1       2-4       5-6       1         serving       S       M       L       Medium       Serving       Never       Less       1-3       1       2-4       5-6       1         serving       S       M       L       Medium       Serving       Never       Less       1-3       1       2-4       5-6       1         serving       S       M       L       Medium       Serving       Never       Less       1-3       1       2-4       5-6       1         serving       S       M       L       Medium       Serving       Never       Less       1-3       1       2-4       5-6       1         serving       S       M       L       Medium       Serving       Never       Less       1-3       1       1       2-4       5-6       1         serving       S       M       L       Medium       Medium       Never       Less       1-3       1       1       2-4       3-6       1         Store bought mushrooms       1 cup       I       I       I       I       I       I       I <td>e.g okra, onion, tomato, garden</td> <td></td> <td></td> <td><u> </u></td> <td></td> <td></td> <td></td> <td></td> <td> </td> <td></td> <td></td> <td></td> <td> </td>	e.g okra, onion, tomato, garden			<u> </u>									
Medium serving       Serving       Never       Less than once a month       1-3 times times a       1       2-4 times times times a       1         Store bought mushrooms       1 cup       Image: Complex time time time time time time time time	egg, cucumber, carrot, pepper												
Medium serving       Serving       Never       Less than once a month       1-3 times times a       1       2-4 times times times a       1         Store bought mushrooms       1 cup       Image: Complex time time time time time time time time													
serving       S       M       L       than       times       time       times       times       times       times       times       times       times       times       times       a	egg, cucumber, carrot, pepper Other	f photograpl	hic g	uide)									I
Store bought mushrooms     1 cup     once a month     a     a     a     a     a     a       Wild mushrooms     1 cup     once a month     once a month     a     month     week     week     week     day	egg, cucumber, carrot, pepper Other					Never	Less	1-3	1	2-4	5-6	1	2 0
Store bought mushrooms     1 cup     month     month     week     week     week     day       Wild mushrooms     1 cup  <	egg, cucumber, carrot, pepper Other	Medium	Ser	ving	L	Never							
Store bought mushrooms     1 cup     Image: Comparison of the compa	egg, cucumber, carrot, pepper Other	Medium	Ser	ving	L	Never	than	times	time	times	times	time	mo
Wild mushrooms   1 cup	egg, cucumber, carrot, pepper Other	Medium	Ser	ving	L	Never	than once a	times a	time a	times a	times a	time a	mo tim
	egg, cucumber, carrot, pepper Other Mushrooms and Products (Page 1 o	Medium serving	Ser	ving	L	Never	than once a	times a	time a	times a	times a	time a	mo tim
Dther I I I I I I I I I I I I I I I I I I I	egg, cucumber, carrot, pepper Other	Medium serving 1 cup	Ser	ving	L	Never	than once a	times a	time a	times a	times a	time a	2 or mor tim a da

	Medium	Se	rving		Never	Less	1-3	1	2-4	5-6	1	2 o
	serving	S	M	L		than once a	times a	time a	times a	times a	time a	ma tin
						month	month	week	week	week	day	a c
Common Salt	1 teaspoon											
Fermented seasoning age	nt 1 wrap											
e.g Iru, ogiri												
Honey	1 teaspoon											
White sugar	5 cubes or 1 teaspoon											
Artificial sweeteners	1/2											
e.g saccharin	teaspoon											
Oils e.g palm oil, vegetable oil, groundnut oil	1 tablespoon											
Other seasonings	1											
e.g ground dried crayfish, fish, ogbonno, dried pepp												
Other												
Physical History												
<b>59.</b> <u>CURRENTLY</u> , does your carrying light loads, walking								a table, ] No	pushing	a vacuun	n cleane	er,
	g briskly)? 🗌 Yes, limi	ted a	little	e [	Yes, lin	nited a lot		-	pushing	a vacuun	n cleane	ır,
*NOTE: Questions 60 and 6 *NOTE: Questions 60 and 6 60. (FOR CASES ADD: When breathing, heart rate, or sw continuously? ☐ Yes [ ↓ If yes	s briskly)?  Yes, limi <b>51 are strictly about a</b> you were well) Does/	ted a ctivit ′did y ′liftir 61) many	y rela y rela your \ ng he	e [ <b>ated</b> WOR avy l	Yes, lin <b>to your t</b> K require oads, dig you do t	nited a lot work* e any vigon ging or co	rous inter instructio	] No Isity acti n work,	vity that etc) for a	caused i at least 1	ncrease 0 minut	s in es
*NOTE: Questions 60 and 6 60. (FOR CASES ADD: When breathing, heart rate, or sw continuously? ☐ Yes [ ↓ If yes 60a. In a t ☐ 1 day 60b. In a t ☐ 10-29	g briskly)? Yes, limit <b>1 are strictly about a</b> you were well) Does/ eating (ex. carrying or No (go to question typical week, on how r 3-4 days typical day, for how lo minutes 3	ted a ctivit 'did y ' liftir 61) many [ ng di 0-59	y rela y rela y our M ng he y days 2-	e [ ated WOR avy l a did 3 da u do u do utes	Yes, lin to your v K require oads, dig you do t ys [	hited a lot work* a any vigor ging or co hese vigor 5+ days	rous inter instructio rous inten s ensity acti	] No Isity acti n work, sity acti	vity that etc) for a vities as part of hours	caused i at least 1 part of y	ncrease 0 minut our wor	s in es
<ul> <li>kNOTE: Questions 60 and 6</li> <li>60. (FOR CASES ADD: When breathing, heart rate, or sw continuously? ☐ Yes [ ↓ If yes 60a. In a t ☐ 1 day 60b. In a t ☐ 10-29 ☐ 2.1 - 3</li> <li>61. (FOR CASES ADD: When loads, gardening, etc) for at ☐ Yes [ ↓ If yes 4</li> </ul>	s briskly)? Yes, limit <b>1 are strictly about and</b> you were well) Does/ reating (ex. carrying or No (go to question typical week, on how r 3-4 days typical day, for how lo minutes 3 hours 3 you were well) Does/ least 10 minutes cont No (go to question	ted a ctivit (did y liftir 61) many [ 0-59 .1 – ! (did y tinuc 62)	vour \ vour \ ng he days 2- d you minu 5 hou vour \ vour \	e [ mted WOR avy I 3 dad 1 do 1 do 1 tes Irs WOR	Yes, lin to your v K require oads, dig you do t ys [ these vig [ K require	hited a lot work* any vigor ging or co hese vigor 5+ days orous inte 1 hour 5.1 – 7 any mod	rous inter onstructio rous inten ensity acti hours erate inte	] No sity acti n work, sity acti vities as ] 1.1 – 2 ] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex	caused i at least 1 part of y your wor	increase 0 minut our wor k? g, carryin	s in es k? ng li
<ul> <li>kNOTE: Questions 60 and 6</li> <li>60. (FOR CASES ADD: When breathing, heart rate, or sw continuously? ☐ Yes [ ↓ If yes 60a. In a t ☐ 1 day</li> <li>60b. In a t ☐ 10-29 ☐ 2.1 - 5</li> <li>61. (FOR CASES ADD: When loads, gardening, etc) for at ☐ Yes [ ↓ If yes 6</li> <li>61a. In a t ☐ 1 day</li> </ul>	s briskly)? Yes, limit <b>1 are strictly about and</b> you were well) Does/ reating (ex. carrying or No (go to question typical week, on how r 3-4 days typical day, for how lo minutes 3 hours you were well) Does/ least 10 minutes cont No (go to question typical week, on how r 3-4 days	ted a ctivit (did y liftir 61) many [ 0-59 .1 – ! (did y tinuc 62) many	little y rela y our \ ng he days 2- d you minu cour \ your \ yously?	e [ mated WOR avy I s did 3 da u do utes irs WOR s did 3 da a work a work a work a a a a a a a a a a a a a	Yes, lin to your v K require oads, dig you do t ys K require You do t you do t ys	hited a lot work* any vigor ging or cc hese vigor 5+ days forous inte 1 hour 5.1 – 7 any mod hese mod hese mod 5+ days	rous inter onstructio rous inten ensity acti hours erate inte erate inte	] No Isity acti n work, sity acti vities as ] 1.1 – 2 ] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex tivities a	caused i at least 1 part of y your wor walking s part of	increase 0 minut our wor k? g, carryin your wo	s in es k? ng li
<pre>kNOTE: Questions 60 and 6 for (FOR CASES ADD: When breathing, heart rate, or sw continuously?   Yes   Yes</pre>	s briskly)? Yes, limit <b>1 are strictly about and</b> you were well) Does/ reating (ex. carrying or No (go to question typical week, on how r 3-4 days typical day, for how lo minutes you were well) Does/ least 10 minutes cont No (go to question typical week, on how r 3-4 days typical week, on how r 3-4 days typical day, for how lo minutes 3 - 4 days	ted a ctivit (did y liftir 61) many many (did y tinuc 62) many [ man] [ many [ man] [ [ man] [ [ man] [ man] [ [ man] [ [ man] [ [ man] [ [ man] [ [ man] [ [ ] [ ] [ ] [ ] [ ] ] [ ] ] [ ] ] [ ] ] [ ]	little y rela y our \ ng he days 2- d you minu cour \ your \ yously?	e [ mated WOR avy I s did 3 da u do utes WOR s did 3 da u do utes	Yes, lin to your v K require oads, dig you do t ys K require You do t you do t ys	hited a lot work* any vigor ging or cc hese vigor 5+ days forous inte 1 hour 5.1 – 7 any mod hese mod hese mod 5+ days	rous inter instructio rous inten ensity acti hours erate inte s tensity ac	] No Isity acti n work, sity acti vities as ] 1.1 – 2 ] 7+ hou ensity ac	vity that etc) for a vities as part of y hours rs tivity (ex tivities a as part of hours	caused i at least 1 part of y your wor walking s part of	increase 0 minut our wor k? g, carryin your wo	s in es k?

## BMJ Open

		as many as			1	T	1	r	1	1
	None	Less than 10 minutes	10-29 minutes	30-59 minutes	1 hour	1.1-2 hours	2.1-3 hours	3.1-5 hours	5.1-7 hours	7 or more hours
Walking (to/from work or for exercise)										
Farming										
Collecting water										
Washing clothes (by hand	1)									
Cooking	.,									
Housecleaning										
Lifting heavy objects										
Jogging (slower than 6 minutes/ km)										
Running (6 minutes/km o	r	D.								
faster)										
Bicycling Football							+		}	
Swimming										
Dancing										
Other vigorous activities										
(specify)			$\sim$							
Other moderate activities										
	'									
(specify) <b>3.</b> ( <i>FOR CASES ADD:</i> When ] 10-29 minutes ] 2.1 – 3 hours	n you were 30-59 m 3.1 – 5 l	ninutes			1.1 -	- 2 hours		g or recli	hing in th	e last y
<b>3.</b> ( <i>FOR CASES ADD:</i> When 10-29 minutes 2.1 – 3 hours	30-59 m 3.1 – 5 l	ninutes		hour	1.1 -	- 2 hours		g or reclin	ning in th	e last y
<b>i3.</b> ( <i>FOR CASES ADD:</i> When 10-29 minutes	30-59 m 3.1 – 5 l	ninutes		hour	1.1 -	- 2 hours		g or reclin	hing in th	e last y
<ul> <li><b>3.</b> (FOR CASES ADD: When 10-29 minutes</li> <li>2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> </ul>	30-59 m 3.1 – 5 l	ninutes nours	1 5.	hour 1 – 7 hours	☐ 1.1 - ☐ 7+ h	- 2 hours	5			
<ul> <li><b>3.</b> (FOR CASES ADD: When 10-29 minutes</li> <li>2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs		
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes</li> <li>2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> </ul>	30-59 m 3.1 – 5 l	ninutes nours well) How	frequently ys 1	hour 1 – 7 hours v do/did you	1.1 - 7+ h	- 2 hours ours handle t	:he follow	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes</li> <li>i 2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes</li> <li>2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When Burning waste (trash)</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes</li> <li>2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When Burning waste (trash) Asbestos (from</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li><b>3.</b> (FOR CASES ADD: When 10-29 minutes 2.1 – 3 hours</li> <li><b>Work &amp; Home Exposures</b></li> <li><b>4.</b> (FOR CASES ADD: When Burning waste (trash) Asbestos (from construction)</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes 2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When Burning waste (trash) Asbestos (from construction) Insecticides/pesticides Wastes from operating</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes 2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When Burning waste (trash) Asbestos (from construction) Insecticides/pesticides Wastes from operating</li> </ul>	30-59 m 3.1 – 5 l	nours well) How <b>1-3 da</b>	frequently ys 1	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes 2.1 – 3 hours</li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When Burning waste (trash) Asbestos (from construction) Insecticides/pesticides Wastes from operating industries</li> <li>Cancer Awareness</li> </ul>	30-59 m 3.1 – 5 l	well) How 1-3 da per m	frequently ys 1 onth v	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When 10-29 minutes 2.1 – 3 hours</li> <li>i2.1 – 3 hours</li> <li>i4. (FOR CASES ADD: When exposures 4. (FOR CASES ADD: When exposures 4. (FOR CASES ADD: When exposures are as a second struction) and the second struction and the second struction are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct and the second struct are as a second struct are as a second struct and the second struct are as a second s</li></ul>	30-59 m 3.1 – 5 l Never Never	well) How 1-3 da per m	frequently ys 1 onth v	hour 1 – 7 hours do/did you day per	directly 2-4 da	- 2 hours ours handle t	he follow 5-6 days	ving subs	tances ir	
<ul> <li>i3. (FOR CASES ADD: When <ul> <li>10-29 minutes</li> <li>2.1 – 3 hours</li> </ul> </li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When <ul> <li>Burning waste (trash)</li> <li>Asbestos (from <ul> <li>construction)</li> <li>Insecticides/pesticides</li> </ul> </li> <li>Wastes from operating <ul> <li>industries</li> </ul> </li> <li>Cancer Awareness</li> <li>i5. Prior to today, had you <ul> <li>Yes</li> <li>No (end of que)</li> <li>If yes</li> </ul> </li> </ul></li></ul>	a you were Never ever heard	well) How 1-3 da per m	frequently ys 1 onth v	hour 1 – 7 hours 2 do/did you day per veek	1.1 -   7+ h directly   2-4 da per w	- 2 hours	he follow 5-6 days per weel	ving subs	eryday	the las
<ul> <li>i3. (FOR CASES ADD: When <ul> <li>10-29 minutes</li> <li>2.1 – 3 hours</li> </ul> </li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When <ul> <li>Burning waste (trash)</li> <li>Asbestos (from <ul> <li>construction)</li> <li>Insecticides/pesticides</li> </ul> </li> <li>Wastes from operating <ul> <li>industries</li> </ul> </li> <li>Cancer Awareness</li> <li>i5. Prior to today, had you <ul> <li>Yes</li> <li>No (end of que </li> <li>If yes</li> <li>i5a. Prior to today, which</li> </ul></li></ul></li></ul>	a 30-59 m 3.1 – 5 l Never Never	well) How 1-3 da per m of cancer?	frequently ys 1 onth v	hour 1 – 7 hours do/did you day per veek	1.1 -   7+ h directly   2-4 da per w	- 2 hours	he follow 5-6 days per weel	ving subs	eryday	the las
<ul> <li>i3. (FOR CASES ADD: When <ul> <li>10-29 minutes</li> <li>2.1 – 3 hours</li> </ul> </li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When <ul> <li>Burning waste (trash)</li> <li>Asbestos (from <ul> <li>construction)</li> <li>Insecticides/pesticides</li> <li>Wastes from operating <ul> <li>industries</li> </ul> </li> <li>Cancer Awareness</li> <li>i5. Prior to today, had you <ul> <li>Yes</li> <li>No (end of que </li> <li>If yes</li> <li>i5a. Prior to today, which <ul> <li>Prostate</li> <li>liver</li> </ul> </li> </ul></li></ul></li></ul></li></ul>	a 30-59 m 3.1 – 5 l Never Never	well) How 1-3 da per m of cancer?	1 frequently ys 1 onth v 	hour 1 – 7 hours do/did you day per veek veek ct as many a ct as many a	1.1 -   7+ h directly   2-4 da per w	- 2 hours	he follow 5-6 days per weel	ving subs	eryday	the las
<ul> <li>i3. (FOR CASES ADD: When <ul> <li>10-29 minutes</li> <li>2.1 – 3 hours</li> </ul> </li> <li>Work &amp; Home Exposures</li> <li>i4. (FOR CASES ADD: When <ul> <li>Burning waste (trash)</li> <li>Asbestos (from <ul> <li>construction)</li> <li>Insecticides/pesticides</li> </ul> </li> <li>Wastes from operating <ul> <li>industries</li> </ul> </li> <li>Cancer Awareness</li> <li>i5. Prior to today, had you <ul> <li>Yes</li> <li>No (end of que </li> <li>If yes</li> <li>i5a. Prior to today, which</li> </ul></li></ul></li></ul>	a 30-59 m 3.1 – 5 l Never Never	well) How 1-3 da per m of cancer?	1 frequently ys 1 onth v 	hour 1 – 7 hours do/did you day per veek veek ct as many a ct as many a	1.1 -   7+ h directly   2-4 da per w	- 2 hours	he follow 5-6 days per weel	ving subs	eryday	the las

	Item No	Recommendation	Page No
Title and abstract	1	( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract	4
		(b) Provide in the abstract an informative and balanced summary of	4
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8,9
Objectives	3	State specific objectives, including any prespecified hypotheses	9
Methods			
Study design	4	Present key elements of study design early in the paper	10,11
Setting	5	Describe the setting, locations, and relevant dates, including periods of	10
0	Ū	recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	10
1	-	selection of participants	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	10
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of	11
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	10,11
Study size	10	Explain how the study size was arrived at	10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	11
		applicable, describe which groupings were chosen and why	
Statistical methods	12	( <i>a</i> ) Describe all statistical methods, including those used to control for confounding	12,13
		(b) Describe any methods used to examine subgroups and interactions	12,13
		(c) Explain how missing data were addressed	13
		( <i>d</i> ) If applicable, describe analytical methods taking account of	n/a
		sampling strategy	
		( <u>e</u> ) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	13
*		potentially eligible, examined for eligibility, confirmed eligible,	
		included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	13
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	13,14
-		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable	n/a
		of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	14,15

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	15,16
		estimates and their precision (eg, 95% confidence interval). Make clear	
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	n/a
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	n/a
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and	n/a
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	21
Limitations	19	Discuss limitations of the study, taking into account sources of	21-25
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	21-25
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	21-25
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	1
		study and, if applicable, for the original study on which the present	
		article is based	

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.